Compound as well as preparation method and application thereof

By synthesizing a new compound and using specific reaction steps to improve its binding affinity with ASGPR, the problem of insufficient affinity of ASGPR ligands in the prior art is solved, and liver targeted delivery and target gene expression inhibition are achieved. Efficient, stable and safe medicine.

CN119019354AActive Publication Date: 2024-11-26RIGERNA THERAPEUTICS (BEIJING) CO LTD

Patent Information

Application Number
CN202310597844.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-24
Publication Date
2024-11-26
Estimated Expiration
2043-05-24

AI Technical Summary

Technical Problem

现有的ASGPR配体亲和性不高,难以实现药物或基因的有效肝靶向递送和靶标基因表达调节。

Method used

Provide a compound and its preparation method, which synthesizes targeted ligands through steps such as acetal reaction, electrophilic substitution reaction, dehydroxyprotective reaction and nucleophilic substitution reaction, improves binding affinity with ASGPR, and realizes targeted liver delivery and Target gene expression inhibition.

Benefits of technology

It has achieved efficient delivery targeted to hepatic parenchymal cells, and has the advantages of high activity in vivo, stable efficacy, excellent safety and low toxicity, and is used to treat and prevent hepatogenic diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019354A_ABST
    Figure CN119019354A_ABST
Patent Text Reader

Abstract

The invention relates to the field of nucleic acid medicines, and particularly discloses a compound as shown in a formula (I) as well as a preparation method and application thereof. The targeting ligand and the RNAi medicine prepared from the compound provided by the invention can highly and effectively target parenchymal hepatic cells, can effectively inhibit the expression of target genes in the parenchymal hepatic cells, can be used for treating and / or preventing hepatogenic diseases, and have the advantages of high in-vivo activity, stable and lasting drug effect, excellent safety and low toxicity. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure relates to the field of synthesis, specifically to the field of nucleic acid drugs, and more specifically provides compounds and preparation methods and uses thereof. Background Art

[0002] The asialoglycoprotein receptor (ASGPR), also known as liver lectin, is a transmembrane protein that is prominently and specifically expressed on the cell surface of the liver sinusoids and basolateral side. ASGPR is mainly composed of two subunits, H1 and H2, which together have an endocytic effect. A normal mature hepatocyte has about 500,000 receptor molecules, and about 10% of ASGPR are expressed on the cell membrane. They have the specificity to recognize, bind to, and internalize some glycoproteins with galactosyl and N-acetylgalactosyl at the ends of the blood circulation, allowing them to be metabolized in hepatocytes. Oligonucleotides are conjugated with targeting ligands, and the targeting ligands are used to bind to ASGPR to achieve liver-targeted delivery of oligonucleotides.

[0003] However, the affinity of ASGPR ligands is currently low, which cannot effectively achieve liver-targeted delivery of drugs or genes to achieve the purpose of regulating target gene expression. Summary of the invention

[0004] In view of this, the present disclosure provides compounds and preparation methods and uses thereof.

[0005] The targeting ligands and RNAi drugs prepared using the compounds provided by the present invention can highly effectively target hepatocytes and effectively inhibit the expression of target genes in hepatocytes, and can be used to treat and / or prevent hepatic diseases. They have the advantages of high in vivo activity, stable and long-lasting efficacy, excellent safety and low toxicity.

[0006] In order to achieve the above-mentioned invention object, the present disclosure provides the following technical solutions:

[0007] In the first aspect of the present disclosure, the present disclosure provides a compound represented by formula (I) or a stereoisomer thereof:

[0008]

[0009] wherein p and q are each independently selected from 0, 1, 2 or 3;

[0010] Each n is independently selected from 1, 2, 3, 4 or 5;

[0011] R1 is selected from H or R1', wherein R1' is selected from a hydroxyl protecting group;

[0012] R2 is selected from H or R2', said R2' is selected from Among them, R 2a Selected from secondary amino groups, R 2b Selected from C1-C3 alkoxy substituted with secondary amino or cyano;

[0013] R3 is selected from H or C1-C3 alkoxy;

[0014] Each R4 is independently selected from

[0015] In some specific embodiments of the present disclosure, each R4 is selected from

[0016] In some specific embodiments of the present disclosure, each R4 is selected from

[0017] In some alternative embodiments of the present disclosure, p and q are each independently selected from 0 or 1.

[0018] In some alternative embodiments of the present disclosure, p=1 and q=1.

[0019] In some specific embodiments of the present disclosure, p=1 and q=0.

[0020] In some alternative embodiments of the present disclosure, or p=0 and q=1.

[0021] In some alternative embodiments of the present disclosure, p=0 and q=0.

[0022] In some specific embodiments of the present disclosure, each n is selected from 1.

[0023] In some optional embodiments of the present disclosure, each n is selected from 2.

[0024] In some optional embodiments of the present disclosure, each n is selected from 3.

[0025] In some optional embodiments of the present disclosure, each n is selected from 4.

[0026] In some optional embodiments of the present disclosure, each n is selected from 5.

[0027] For example, when p=1, q=0, and n=1, the structural formula of the compound of formula (I) is

[0028] In some optional embodiments of the present disclosure, the structural formula of the hydroxyl protecting group is Among them, each R 1a Each is independently selected from H, C1-C3 alkyl or C1-C3 alkoxy.

[0029] In some optional embodiments of the present disclosure, each R 1a Each independently selected from H or C1-C3 alkoxy;

[0030] In some optional embodiments of the present disclosure, each R 1a Each is independently selected from H or methoxy.

[0031] In some optional embodiments of the present disclosure, the hydroxyl protecting group is selected from trityl (Tr group), 4-methoxytrityl (MMTr group), 4,4'-dimethoxytrityl (DMTr group) or 4,4',4"-trimethoxytrityl (TMTr group).

[0032] In some specific embodiments of the present disclosure, the hydroxyl protecting group is selected from 4,4'-dimethoxytrityl (DMTr group).

[0033] In some specific embodiments of the present disclosure, R 2a Selected from

[0034] In some optional embodiments of the present disclosure, R 2b Selected from

[0035] In some specific embodiments of the present disclosure, R 2b Selected from Selected from

[0036] In some optional embodiments of the present disclosure, Selected from

[0037] In some specific embodiments of the present disclosure, Selected from

[0038] In some optional embodiments of the present disclosure, R2 is selected from H,

[0039] In some optional embodiments of the present disclosure, R2 is selected from H or

[0040] In some specific embodiments of the present disclosure, R2 is selected from H.

[0041] In some specific embodiments of the present disclosure, R2 is selected from

[0042] In some optional embodiments of the present disclosure, the compound is selected from any of the following structures:

[0043]

[0044] In some optional embodiments of the present disclosure, the compound is selected from any of the following structures:

[0045]

[0046] In a second aspect of the present disclosure, the present disclosure provides a method for preparing a compound, wherein the compound is represented by formula (I-1a), formula (I-1b), or formula (I-1c):

[0047]

[0048] Wherein, R1', R2', R3, p, q, n are as defined above;

[0049] The preparation method comprises the following steps:

[0050]

[0051] S1-1, the compound of formula (1) and the compound of formula (2) undergo acetalization reaction in the presence of an acidic catalyst to obtain a compound of formula (3); wherein R5 is selected from a substituted or unsubstituted C6-C12 aromatic group;

[0052] S1-2, the compound of formula (3), the hydrogenated salt and the compound of formula (4) undergo electrophilic substitution reaction to obtain a compound of formula (5); wherein X1 represents a halogen;

[0053] S1-3, the compound of formula (5) undergoes a dehydroxylation reaction under acidic conditions to obtain a compound of formula (I-1a);

[0054] S1-4, the compound of formula (I-1a) and the compound of formula (6) undergo a nucleophilic substitution reaction to obtain a compound of formula (I-1b); wherein X2 represents a halogen;

[0055] S1-5, the compound of formula (I-1b) and the compound of formula (7) undergo condensation reaction to obtain a compound of formula (I-1c); wherein R 2c is selected from halogen or secondary amino.

[0056] In some optional embodiments of the present disclosure, in step S1-1, the molar ratio of the compound of formula (1), the compound of formula (2) and the acidic catalyst is 1:(2-4):(0.01-0.2). For example, 1:(2.5-3.5):(0.01-0.2), 1:(2.8-3.2):(0.01-0.2), 1:3:(0.01-0.2), 1:(2-4):(0.05-0.15), 1:(2-4):(0.08-0.12), 1:(2-4):0.1, 1:3:0.1, etc.

[0057] In some specific embodiments of the present disclosure, in step S1-1, the molar ratio of the compound of formula (1), the compound of formula (2) and the acidic catalyst is 1:3:0.1.

[0058] In some specific embodiments of the present disclosure, in step S1-1, the acidic catalyst is selected from sulfonic acid catalysts.

[0059] In some specific embodiments of the present disclosure, the sulfonic acid catalyst is selected from DL-10-camphorsulfonic acid (CAS No. 5872-08-2).

[0060] In some optional embodiments of the present disclosure, in step S1-1, the reaction temperature of the acetal reaction is selected from 20 to 40°C; for example, 25°C, 30°C, 35°C, etc.

[0061] In some optional embodiments of the present disclosure, in step S1-1, the reaction time of the acetal reaction is 4 to 10 h, for example, 4.5 h, 5 h, 5.5 h, 6 h, 6.5 h, 7 h, 7.5 h, 8 h, 8.5 h, 9 h, 9.5 h, etc.

[0062] In some optional embodiments of the present disclosure, in step S1-1, the reaction solvent of the acetal reaction is a polar aprotic solvent, such as acetonitrile.

[0063] In some specific embodiments of the present disclosure, in step S1-1, R5 is selected from phenyl (Ph group).

[0064] In some optional embodiments of the present disclosure, in step S1-2, the molar ratio of the compound of formula (3), the compound of formula (4) and the catalyst is 1:(3-5):(3-5); for example, 1:(3.5-4.5):(3-5), 1:(3.8-4.2):(3-5), 1:4:(3-5), 1:(3-5):(3.5-4.5), 1:(3-5):(3.8-4.2), 1:(3-5):4, 1:4:4.

[0065] In some specific embodiments of the present disclosure, in step S1-2, the molar ratio of the compound of formula (3), the compound of formula (4) and the catalyst is 1:4:4.

[0066] In some optional embodiments of the present disclosure, in step S1-2, the hydride salt is selected from sodium hydride, potassium hydride or magnesium hydride.

[0067] In some specific embodiments of the present disclosure, in step S1-2, the hydride salt is selected from sodium hydride.

[0068] In some optional embodiments of the present disclosure, in step S1-2, the conditions of the electrophilic substitution reaction are: the compound of formula (3) and the hydrogenated salt are first reacted at -10 to 0°C (e.g., -9°C, -8°C, -7°C, -6°C, -5°C, -4°C, -3°C, -2°C, -1°C, etc.) for 25 to 35 min (e.g., 30 min, etc.), and then the compound of formula (4) is added and reacted at 20 to 40°C (e.g., 25°C, 30°C, 35°C, etc.) for 1 to 5 h (e.g., 1.5 h, 2 h, 2.5 h, 3 h, 3.5 h, 4 h, 4.5 h, etc.).

[0069] In some optional embodiments of the present disclosure, in step S1-2, the reaction solvent of the electrophilic substitution reaction is a polar aprotic solvent, such as N,N-dimethylformamide (DMF).

[0070] In some specific embodiments of the present disclosure, in step S1-2, X1 is selected from bromine (Br).

[0071] In some optional embodiments of the present disclosure, in step S1-3, the acidic condition is: an organic acid. The organic acid can be selected from formic acid (CAS No. 64-18-6), acetic acid (CAS No. 64-19-7), propionic acid (CAS No. 79-09-4), butyric acid (CAS No. 107-92-6) and valeric acid (CAS No. 109-52-4).

[0072] In some specific embodiments of the present disclosure, in step S1-3, the acidic condition is: acetic acid, specifically: 50-80 mass % acetic acid aqueous solution, more specifically: 70 mass % acetic acid aqueous solution.

[0073] In some optional embodiments of the present disclosure, in step S1-3, the reaction temperature of the dehydroxylation protection reaction is selected from 60 to 80°C; for example, 65°C, 70°C, 75°C, etc.

[0074] In some optional embodiments of the present disclosure, in step S1-3, the reaction solvent of the deprotection reaction is a polar aprotic solvent, such as dichloromethane (DCM).

[0075] In some optional embodiments of the present disclosure, in step S1-4, the molar ratio of the compound of formula (I-1a) to the compound of formula (6) is 1:(1.1-1.5); for example, 1:1.15, 1:1.2, 1:1.25, 1:1.3, 1:1.35, 1:1.4, 1:1.45, etc.

[0076] In some optional embodiments of the present disclosure, in step S1-4, the compound of formula (6) is selected from trityl chloride (also known as triphenylmethane chloride, abbreviated as Trt-Cl, CAS No. 76-83-5), trityl bromide (CAS No. 596-43-0), 4-methyltriphenylmethyl chloride (also known as 4-methyltriphenylmethane chloride, CAS No. 23429-44-9), 4-methoxytrityl chloride (also known as 4-methoxytriphenylmethane chloride, MMT-Cl, CAS No. 14470-28-1), 4,4'-dimethoxytrityl chloride (also known as 4,4'-dimethoxytriphenylmethane chloride, abbreviated as DMT-Cl, CAS No. 40615-36-9) and 4,4',4"-trimethoxytrityl chloride (CAS No. 49757-42-8).

[0077] In some specific embodiments of the present disclosure, in step S1-4, the compound of formula (6) is selected from 4,4'-dimethoxytrityl chloride.

[0078] In some specific embodiments of the present disclosure, in step S1-4, the nucleophilic substitution reaction is carried out in an inert atmosphere, such as nitrogen, helium, etc.

[0079] In some optional embodiments of the present disclosure, in step S1-4, the reaction temperature of the nucleophilic substitution reaction is selected from 20 to 40°C; for example, 25°C, 30°C, 35°C, etc.

[0080] In some optional embodiments of the present disclosure, in step S1-4, the reaction time of the nucleophilic substitution reaction is 2 to 5 h, for example: 2.5 h, 3 h, 3.5 h, 4 h, 4.5 h, etc.

[0081] In some specific embodiments of the present disclosure, in step S1-4, X2 is selected from bromine (Br).

[0082] In some optional embodiments of the present disclosure, in step S1-5, the molar ratio of the compound of formula (I-1b) to the compound of formula (7) is 1:(0.6-0.9); for example, 1:0.65, 1:0.7, 1:0.71, 1:0.72, 1:0.73, 1:0.74, 1:0.75, 1:0.76, 1:0.77, 1:0.78, 1:0.79, 1:0.8, 1:0.85, etc.

[0083] In some specific embodiments of the present disclosure, in step S1-5, the molar ratio of the compound of formula (I-1b) to the compound of formula (7) is 1.5:1.1 (approximately 1:0.73).

[0084] In some optional embodiments of the present disclosure, in step S1-5, the compound of formula (7) is selected from 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite (CAS No. 89992-70-1), bis(diisopropylamino)chlorophosphine and bis(diisopropylamino)(2-cyanoethoxy)phosphine (CAS No. 102691-36-1).

[0085] Compared with bis(diisopropylamino)(2-cyanoethoxy)phosphine, 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite is not only expensive, but also highly active and easily deteriorates; since the use and storage of 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite are not very convenient, it is also easier to introduce other impurities during the reaction process, resulting in less than ideal purity and yield. Therefore, those skilled in the art are more inclined to choose bis(diisopropylamino)(2-cyanoethoxy)phosphine, and it is well known in the art that bis(diisopropylamino)(2-cyanoethoxy)phosphine must undergo a condensation reaction with alcohol under the catalysis of a weakly acidic reagent (such as tetrazole, 4,5-dicyanoimidazole, etc.). In some specific embodiments of the present disclosure, in step S1-5, the compound of formula (7) is selected from 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite.

[0086] In some optional embodiments of the present disclosure, in step S1-5, R 2c Selected from halogen.

[0087] In some specific embodiments of the present disclosure, in step S1-5, R 2c Selected from chlorine (Cl).

[0088] In some optional embodiments of the present disclosure, in step S1-5, the condensation reaction is carried out in an inert atmosphere, such as nitrogen, helium, etc.

[0089] In some optional embodiments of the present disclosure, in step S1-5, the reaction solvent of the condensation reaction is a polar aprotic solvent, for example: dichloromethane.

[0090] When R3 is selected from H, the structural formula of the compound of formula (1) is The compound of formula (1) (R3 is selected from H) can be purchased from the market, but the price is relatively high. In order to save costs, the compound of formula (1) (R3 is selected from H) can be obtained by the following preparation method.

[0091] In some specific embodiments of the present disclosure, the method for preparing the compound of formula (1) (R3 is selected from H) comprises the following steps:

[0092]

[0093] Step 1: The compound of formula (1-a) undergoes a hydrodehalogenation reaction in the presence of a reducing agent and a free radical initiator to obtain a compound of formula (1b); wherein X4 represents a halogen (such as F, Cl, Br, I);

[0094] Step 2: The compound of formula (1b) undergoes hydrolysis reaction to obtain a compound of formula (1).

[0095] In some optional embodiments of the present disclosure, in step one, the molar ratio of the compound of formula (1-a), the reducing agent and the free radical initiator is 1:(0.9-1.2):(0.01-0.2), for example, 1:(0.95-1.2):(0.01-0.2), 1:(0.95-1.1):(0.01-0.2), 1:(0.98-1.05):(0.01-0.2), 1:(0.98-1.02):(0.01-0.2), 1:1:(0.01-0.2), 1:(0.9-1.2):(0.05-0.15), 1:(0.9-1.2):(0.08-0.12), 1:(0.9-1.2):0.1, 1:1:0.1, etc.

[0096] In some specific embodiments of the present disclosure, in step 1, the molar ratio of the compound of formula (1-a), the reducing agent and the free radical initiator is 1:1:0.1.

[0097] In some specific embodiments of the present disclosure, in step 1, the reducing agent is tributyltin hydride.

[0098] In some optional embodiments of the present disclosure, in step 1, the free radical initiator is an azo initiator, wherein the azo initiator may be azobisisobutyronitrile.

[0099] In some optional embodiments of the present disclosure, in step 1, the reaction temperature of the hydrodehalogenation reaction is 100-120°C, for example: 105°C, 110°C, 115°C, etc.

[0100] In some optional embodiments of the present disclosure, in step 1, the reaction solvent of the hydrodehalogenation reaction is an aprotic solvent, such as toluene.

[0101] In some optional embodiments of the present disclosure, in step one, the reaction time of the hydrodehalogenation reaction is 1-5 h, for example, 1.5 h, 2 h, 2.5 h, 3 h, 3.5 h, 4 h, 4.5 h, etc.

[0102] In some optional embodiments of the present disclosure, in step 2, the hydrolysis reaction is an alkaline hydrolysis reaction.

[0103] In some optional embodiments of the present disclosure, in step 2, the conditions for the alkaline hydrolysis reaction are: C1-C3 alkoxide and C1-C3 alcohol.

[0104] In some optional embodiments of the present disclosure, the C1-C3 alkoxide is selected from lithium methoxide, sodium methoxide, potassium methoxide, rubidium methoxide, cesium methoxide, lithium ethoxide, sodium ethoxide, potassium ethoxide, sodium n-propoxide, potassium n-propoxide, sodium isopropoxide and potassium isopropoxide.

[0105] In some specific embodiments of the present disclosure, the C1-C3 alkoxide is selected from lithium methoxide.

[0106] In some optional embodiments of the present disclosure, the C1-C3 alcohol is selected from methanol, ethanol, n-propanol and isopropanol.

[0107] In some specific embodiments of the present disclosure, the C1-C3 alcohol is selected from methanol.

[0108] In some optional embodiments of the present disclosure, in step 2, the molar ratio of the compound of formula (1-b) to the alkoxide is 1:(0.05-0.2), for example 1:0.06, 1:0.07, 1:0.08, 1:0.09, 1:0.1, 1:0.11, 1:0.12, 1:0.13, 1:0.14, 1:0.15, 1:0.16, 1:0.17, 1:0.18, 1:0.19.

[0109] In the second aspect of the present disclosure, the present disclosure provides a method for preparing a compound, wherein the compound is as shown in formula (I-2):

[0110]

[0111] Wherein, R1', R3, p, q, n are as defined above;

[0112] The preparation method comprises the following steps:

[0113]

[0114] S2-1, the compound of formula (3), the hydride salt, the compound of formula (8) and the iodide salt undergo electrophilic substitution reaction to obtain a compound of formula (9); wherein R5 is selected from substituted or unsubstituted C6-C12 aryl, X3 represents halogen, and R6 is selected from substituted or unsubstituted C1-C5 alkyl;

[0115] S2-2, the compound of formula (9) undergoes a dehydroxylation reaction under acidic conditions to obtain a compound of formula (10);

[0116] S2-3, the compound of formula (10) and the compound of formula (6) undergo a nucleophilic substitution reaction to obtain a compound of formula (11);

[0117] S2-4, the compound represented by formula (11) undergoes hydrolysis reaction to obtain a compound represented by formula (I-2).

[0118] In some optional embodiments of the present disclosure, in step S2-1, the molar ratio of the compound of formula (3), the hydrogenated salt, the compound of formula (8) and the iodide salt is 1:(3-5):(1.5-2.5):(1-2); for example, 1:(3.5-4.5):(1.5-2.5):(1-2), 1:(3.8-4.2):(1.5-2.5):(1-2), 1:4:(1.5-2.5):(1-2), 1:(3~5):(1.8~2.2):(1~2), 1:(3~5):(1.9~2.1):(1~2), 1:(3~5):2:(1~2), 1:(3~5):(1.5~2.5):(1.3~1.7), 1:(3~5):(1.5~2.5):(1.4~1.6), 1:(3~5):(1.5~2.5):1.5, 1:4:2:1.5, etc.

[0119] In some specific embodiments of the present disclosure, in step S2-1, the molar ratio of the compound of formula (3), the hydrogenated salt, the compound of formula (8) and the iodide salt is 1:4:2:1.5.

[0120] In some optional embodiments of the present disclosure, in step S2-1, the conditions of the electrophilic substitution reaction are: the compound of formula (3) and the hydrogenated salt are first reacted at -10 to 0°C (e.g., -9°C, -8°C, -7°C, -6°C, -5°C, -4°C, -3°C, -2°C, -1°C, etc.) for 0.5 to 1.5 h (e.g., 0.75 h, 1 h, 1.25 h, etc.), and then the compound of formula (8) and the iodide salt are added and reacted at 20 to 40°C (e.g., 25°C, 30°C, 35°C, etc.) for 3 to 5 h (e.g., 3.5 h, 4 h, 4.5 h, etc.).

[0121] In some specific embodiments of the present disclosure, in step S2-1, R5 is selected from phenyl (Ph group);

[0122] In some optional embodiments of the present disclosure, in step S2-1, R6 is selected from substituted or unsubstituted C1~C3 alkyl.

[0123] In some specific embodiments of the present disclosure, in step S2-1, R6 is selected from ethyl.

[0124] In some optional embodiments of the present disclosure, in step S2-2, the acidic condition is: an organic acid; wherein the organic acid can be selected from formic acid (CAS No. 64-18-6), acetic acid (CAS No. 64-19-7), propionic acid (CAS No. 79-09-4), butyric acid (CAS No. 107-92-6) and valeric acid (CAS No. 109-52-4).

[0125] In some specific embodiments of the present disclosure, in step S2-2, the acidic condition is acetic acid, specifically 50-80 mass % acetic acid aqueous solution, more specifically 70 mass % acetic acid aqueous solution.

[0126] In some optional embodiments of the present disclosure, in step S2-2, the reaction temperature of the dehydroxylation protection reaction is selected from 40 to 60°C; for example, 45°C, 50°C, 55°C, etc.

[0127] In some optional embodiments of the present disclosure, in step S2-3, the molar ratio of the compound of formula (10) to the compound of formula (6) is 1:(1.1-1.5), for example, 1:1.15, 1:1.2, 1:1.25, 1:1.3, 1:1.35, 1:1.4, 1:1.45, etc.

[0128] In some specific embodiments of the present disclosure, in step S2-3, the molar ratio of the compound of formula (10) to the compound of formula (6) is 1:1.3.

[0129] In some optional embodiments of the present disclosure, in step S2-3, the reaction temperature of the nucleophilic substitution reaction is selected from 20 to 40°C; for example, 25°C, 30°C, 35°C, etc.

[0130] In some optional embodiments of the present disclosure, in step S2-4, the hydrolysis reaction is selected from an alkaline hydrolysis reaction.

[0131] In some optional embodiments of the present disclosure, in step S2-4, the hydrolysis reaction conditions are selected from 0.5 to 1.5 mol / L NaOH aqueous solution, such as 0.8 mol / L NaOH aqueous solution, 1 mol / L NaOH aqueous solution, 1.2 mol / L NaOH aqueous solution, etc.

[0132] In some optional embodiments of the present disclosure, in step S2-4, the temperature of the hydrolysis reaction is 20-40°C; for example, 25°C, 30°C, 35°C, etc.

[0133] In a fourth aspect of the present disclosure, the present disclosure provides use of the compound of the first aspect in preparing a targeting ligand capable of binding to a cell surface receptor.

[0134] In some specific embodiments of the present disclosure, the receptor is selected from asialoglycoprotein receptor.

[0135] Exemplarily, the targeting ligand is selected from any of the following compounds:

[0136]

[0137]

[0138]

[0139]

[0140] In a fourth aspect of the present disclosure, the present disclosure provides use of the compound of the first aspect in preparing a medicament for reducing the expression or activity of a target gene in hepatic parenchymal cells.

[0141] In some specific embodiments of the present disclosure, the target cells are selected from hepatocytes.

[0142] In some specific embodiments of the present disclosure, the drug is selected from RNAi drugs;

[0143] In some specific embodiments of the present disclosure, the drug is selected from siRNA drugs.

[0144] Exemplarily, the siRNA drug is selected from any of the following compounds:

[0145]

[0146]

[0147]

[0148] in, Represents siRNA. Wherein, when there is one targeting ligand in the siRNA drug, one targeting ligand is conjugated to the 3' end of the sense strand. When there are two targeting ligands in the siRNA drug, the two targeting ligands are conjugated to the 3' end and the 5' end of the sense strand, respectively.

[0149] Beneficial effects:

[0150] The targeting ligands and RNAi drugs (e.g., siRNA drugs) prepared using the compounds provided by the present invention can be highly and effectively targeted to hepatic parenchymal cells and effectively inhibit the expression of target genes in hepatic parenchymal cells, and can be used to treat and / or prevent pathological conditions or diseases caused by abnormal expression of target genes in hepatic parenchymal cells, and have the advantages of high in vivo activity, stable and long-lasting efficacy, excellent safety, and low toxicity. BRIEF DESCRIPTION OF THE DRAWINGS

[0151] Figure 1 This is a graph showing the inhibitory activity of RZ802010 and RZ502031 of Example 1 of the present disclosure on the target gene CC3 in mice;

[0152] Figure 2 This is a graph showing the inhibitory activity results of RZ899009, RZ899011 and RZ599001 of Example 2 of the present disclosure on the target gene SOD1 in mice;

[0153] Figure 3 This is a graph showing the inhibitory activity results of RZ899011, RZ899040 and RZ599001 of Example 3 of the present disclosure on the target gene SOD1 in mice;

[0154] Figure 4 This is a graph showing the inhibitory activity of RZ802011 and RZ502031 of Example 4 of the present disclosure on the target gene CC3 in mice; Figure 5 This is a graph showing the inhibitory activity results of RZ899048, RZ899011 and RZ599001 of Example 5 of the present disclosure on the target gene SOD1 in mice; Figure 6 This is a graph showing the inhibitory activity of RZ899038, RZ899011 and RZ599001 of Example 6 of the present disclosure on the target gene SOD1 in mice; Figure 7 This is a graph showing the inhibitory activity results of RZ899041, RZ899042, RZ899038 and RZ599001 of Example 7 of the present disclosure on the target gene SOD1 in mice; Figure 8a This is a graph showing the results of AST in the blood of mice injected with RZ899011 and RZ899038 in Example 8 of the present disclosure; Figure 8b This is a graph showing the results of ALT in the blood of mice injected with RZ899011 and RZ899038 in Example 8 of the present disclosure; Figure 8c This is a graph showing the results of TBIL in the blood of mice injected with RZ899011 and RZ899038 in Example 8 of the present disclosure; Figure 8d This is a graph showing the results of Urea in the blood of mice injected with RZ899011 and RZ899038 in Example 8 of the present disclosure; Figure 8e This is a graph showing the results of Crea in the blood of mice injected with RZ899011 and RZ899038 in Example 8 of the present disclosure; Figure 8f This is a graph showing the TC results in the blood of mice injected with RZ899011 and RZ899038 in Example 8 of the present disclosure; Figure 8g This is a graph showing the TG results in the blood of mice injected with RZ899011 and RZ899038 in Example 8 of the present disclosure; Figure 8h This is a graph showing the results of WBC in the blood of mice injected with RZ899011 and RZ899038 in Example 8 of the present disclosure; Figure 8i This is a graph showing the NEUT results in the blood of mice injected with RZ899011 and RZ899038 in Example 8 of the present disclosure; Figure 8j This is a graph showing the results of LYMPH in the blood of mice injected with RZ899011 and RZ899038 in Example 8 of the present disclosure; Figure 8k This is a graph of the results of liver tissue pathology staining after RZ899011 and RZ899038 were injected into mice in Example 8 of the present disclosure. DETAILED DESCRIPTION

[0155] The present disclosure discloses compounds and methods for preparing and using the compounds. Those skilled in the art can refer to the contents of this article and appropriately improve the process parameters to achieve the above. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art and are deemed to be included in the present disclosure. The methods and applications of the present disclosure have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit and scope of the present disclosure to implement and apply the disclosed technology.

[0156] The affinity of ASGPR to ligand is mainly affected by the following factors:

[0157] a. Type of ligand terminal sugar molecules. Ligand molecules with Gal or GalNAc at the end can be recognized by ASGPR. The affinity of GalNAc binding to ASGPR is 10 to 50 times higher than that of Gal. Moreover, GalNAc ligand molecules are more likely to escape the recognition of Kupffer cells and target more hepatic parenchymal cells.

[0158] b. Sugar molecule substitution site: 1-OH, 2-OH (or 2-amino), 3-OH, 4-OH and 5-CH2- on Gal (or GalNAc) are all involved in the binding of ASGPR receptors; when 5-CH2- is connected to a negatively charged group or 4-OH, 3-OH, 2-OH (or 2-amino) is replaced, the affinity with the receptor drops sharply; when 1-OH is glycosylated and replaced, when the glycosidic bond is in the α conformation, the affinity with the receptor is weakened, and when it is in the β conformation and the substituent is a straight chain structure, the affinity is not affected; only 6-OH does not participate in receptor binding and points to the solvent region, so it is suitable as a connection site to connect with carriers, drugs, etc.

[0159] c. Spatial distance between the terminal sugar group and the carrier: ASGPR can effectively recognize sugar groups when there are at least 6 CH2 units between the sugar group and the carrier.

[0160] also, Ligands with different molecular cluster structures Different connection modes between oligonucleotides will significantly affect the activity of oligonucleotides in the body. Higher activity means better therapeutic effect or lower dosage. Under the same efficacy, lower dosage also means lower toxicity.

[0161] Based on the affinity characteristics of the ASGPR receptor mentioned above, we designed a ligand with high affinity for ASGPR to achieve liver-targeted delivery of drugs or genes to achieve the purpose of regulating target gene expression.

[0162] Explanation of terms

[0163] the term Indicates the site where a group is attached via a covalent bond.

[0164] In the structural formula of the compound or ligand disclosed herein, the bond "-" indicates that the configuration is not specified. If chiral isomerism exists in the chemical structure, the bond "-" can be or include both Although all of the above structural formulae are drawn in certain isomeric forms for simplicity, the present disclosure may include all isomers, for example, tautomers, rotational isomers, geometric isomers, diastereomers, racemates, and enantiomers.

[0165] Unless otherwise indicated, the following definitions used herein shall apply. For purposes of this disclosure, chemical elements are consistent with the Periodic Table of the Elements, CAS version, and Handbook of Chemistry and Physics, 75th edition, 1994. In addition, general principles of organic chemistry can be found in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999, and "March's Advanced Organic Chemistry" by Michael B. Smith and Jerry March, John Wiley & Sons, New York: 2007, the entire contents of which are incorporated herein by reference.

[0166] Unless otherwise specified or there is a clear conflict in context, the articles "a", "an", and "the" as used herein are intended to include "at least one" or "one or more". Therefore, these articles as used herein refer to one or more than one (i.e., at least one) of the objects. For example, "a component" refers to one or more components, i.e., there may be more than one component that is contemplated for use or use in the implementation of the described embodiment.

[0167] The term "comprising" is an open expression, that is, including the contents specified in the present disclosure but not excluding other contents.

[0168] "Stereoisomers" refer to compounds that have the same chemical constitution but differ in the way the atoms or groups are arranged in space. Stereoisomers include enantiomers, diastereomers, conformational isomers (rotamers), geometric isomers (cis / trans) isomers, atropisomers, and the like.

[0169] "Chiral" refers to a molecule that is non-superimposable on its mirror image; "achiral" refers to a molecule that is superimposable on its mirror image.

[0170] "Enantiomers" refer to two non-superimposable isomers of a compound that are mirror images of each other.

[0171] "Diastereoisomers" refers to stereoisomers that have two or more chiral centers and whose molecules are not mirror images of each other. Diastereoisomers have different physical properties, such as melting points, boiling points, spectral properties, and reactivity. Diastereomeric mixtures can be separated by high resolution analytical procedures such as electrophoresis and chromatography, for example HPLC.

[0172] The stereochemical definitions and conventions used in this disclosure generally follow SP Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., "Stereochemistry of Organic Compounds", John Wiley & Sons, Inc., New York, 1994.

[0173] In the context of the present disclosure, unless otherwise specified, "conjugation" refers to the connection between two or more chemical moieties, each having a specific function, in a covalent manner; accordingly, "conjugate" refers to a compound formed by covalently connecting the chemical moieties. Further, "drug conjugate" refers to a compound formed by covalently connecting one or more chemical moieties with specific functions to an active drug. In the following, sometimes, especially in the examples, the drug conjugates of the present disclosure are also referred to as "conjugates". Drug conjugates should be understood as a general term for drug conjugates or a specific drug conjugate represented by a specific structural formula, depending on the context.

[0174] In general, the term "substituted" means that one or more hydrogen atoms in a given structure are replaced by a specified substituent. Unless otherwise indicated, a substituted group may have a substituent at each substitutable position of the group. When more than one position in a given structure can be substituted by one or more substituents selected from a specified group, then the substituents may be the same or different at each substitutable position.

[0175] The term "unsubstituted" means that the designated group bears no substituents.

[0176] The term "optionally substituted with" can be used interchangeably with the term "unsubstituted or substituted with", i.e., the structure is unsubstituted or substituted with one or more substituents disclosed herein. Substituents disclosed herein include, but are not limited to, D, F, Cl, Br, I, N3, CN, NO2, OH, SH, NH2, alkyl, haloalkyl, haloalkoxy, haloalkylamino, alkenyl, alkynyl, alkoxy, alkylamino, cycloalkyl, heterocyclyl, aryl, heteroaryl, and the like.

[0177] In addition, it should be noted that, unless otherwise explicitly stated, the description methods used in this disclosure, "each ... is independently" and "... are each independently" and "... are independently" can be interchanged, and should be understood in a broad sense, which can mean that in different groups, the specific options expressed by the same symbols do not affect each other, or that in the same group, the specific options expressed by the same symbols do not affect each other. Taking R3 as an example, the specific options of R3 between the structural formula "C1-C50 alkylene optionally substituted by R3" and the structural formula "-C(O)-NH-C1-50 alkylene optionally substituted by R3" do not affect each other.

[0178] The term "small interfering RNA (siRNA)" refers to a type of double-stranded RNA, comprising a sense strand and an antisense strand, each of which is 17 to 30 nucleotides in length. siRNA mediates the targeted cleavage of RNA transcripts in the RISC pathway by forming a silencing complex (RISC). Specifically, siRNA guides the specific degradation of mRNA sequences through the known RNA interference (RNAi) process, inhibiting the translation of mRNA into amino acids and proteins.

[0179] In the context of this disclosure, "treating," "alleviating," or "amelioration" are used interchangeably herein. These terms refer to an approach for obtaining beneficial or desired results, including but not limited to a therapeutic benefit. "Therapeutic benefit" means eradication or amelioration of the underlying disorder being treated. Here, a therapeutic benefit is obtained by eradication or amelioration of one or more physiological symptoms associated with the underlying disorder, such that an improvement is observed in the subject, although the subject may still be afflicted with the underlying disorder.

[0180] In the context of this disclosure, "prevention" and "prevention" are used interchangeably. These terms refer to an approach to obtaining a beneficial or desired result, including but not limited to a prophylactic benefit. To obtain a "prophylactic benefit," a conjugate, RNAi agent, or composition can be administered to a subject at risk for a particular disease, or to a subject reporting one or more physiological symptoms of a disease, even though a diagnosis of the disease may not have been made.

[0181] The compounds provided in the present disclosure and the raw materials and reagents used in their preparation methods and uses can all be purchased from the market.

[0182] The reagents and reagent sources used in the present disclosure are as follows:

[0183] 1) Tributyltin hydride, CAS No. 688-73-3, purchased from Beijing Coupling Technology Co., Ltd.;

[0184] 2) DL-10-camphorsulfonic acid, CAS No. 5872-08-2, purchased from Beijing Coupling Technology Co., Ltd.;

[0185] 3) 3-bromopropyne, CAS No. 106-96-7, purchased from Beijing Coupling Technology Co., Ltd.;

[0186] 4) 4,4'-bis(methoxytrityl) chloride (abbreviated as DMTrCl), CAS No. 40615-36-9, purchased from Beijing Coupling Technology Co., Ltd.;

[0187] 5) 4,5-dicyanoimidazole (abbreviated as DCI), CAS No. 1122-28-7, purchased from Beijing Coupling Technology Co., Ltd.;

[0188] 6) Bis(diisopropylamino)(2-cyanoethoxy)phosphine, CAS No. 102691-36-1, purchased from Beijing Coupling Technology Co., Ltd.;

[0189] 7) Potassium iodide (KI), CAS No. 7681-11-0, purchased from Shanghai Bid Pharmaceutical Technology Co., Ltd.;

[0190] 8) Trimethylsilyl azide (TMSN3), CAS No. 4648-54-8, purchased from Beijing Coupling Technology Co., Ltd.;

[0191] 9) Potassium fluoride (KF), CAS No. 7789-23-3, purchased from Beijing Coupling Technology Co., Ltd.;

[0192] 10) N,N-dimethylformamide (DMF), CAS No. 68-12-2, purchased from Beijing Coupling Technology Co., Ltd.;

[0193] 11) D-galactosamine pentaacetate, CAS No. 76375-60-5, purchased from Beijing Coupling Technology Co., Ltd.;

[0194] 12) Scandium trifluoromethanesulfonate, CAS No. 144026-79-9, purchased from Beijing Coupling Technology Co., Ltd.;

[0195] 13) Sodium hydride (NaH), CAS No. 7646-69-7, purchased from Beijing Coupling Technology Co., Ltd.;

[0196] 14) Amberlyst-15 (Chinese name: polymer of vinylbenzenesulfonic acid and divinylbenzene, English name: amberlyst 15 ion-exchange resin), CAS No. 39389-20-3, purchased from Beijing Coupling Technology Co., Ltd.;

[0197] 15) Aminoalkyl-CPG (model C3006-1000), purchased from Beijing Coupling Technology Co., Ltd.;

[0198] 16) Succinic anhydride, CAS No. 108-30-5, purchased from Beijing Coupling Technology Co., Ltd.

[0199] Unless otherwise stated, the reagents and consumables (Table 1) and instruments and equipment (Table 2) used in the present disclosure are all commercially available products from the following manufacturers.

[0200] Table 1 Main reagents and consumables

[0201]

[0202]

[0203] Table 2 Main instruments and equipment

[0204] name Manufacturer Fully automatic nucleic acid extraction instrument Zhejiang Hanwei Technology Co., Ltd. High-speed refrigerated centrifuge Eppendorf NANODROP OneC Thermo Fisher Scientific Gradient PCR Amplifier Eppendorf Fluorescence quantitative PCR instrument ABI StepOne Plus Gel Imager Shanghai Tianneng Life Sciences Co., Ltd. Electrophoresis Apparatus Beijing Liuyi Instrument Factory Tissuelyser II fully automatic tissue homogenizer Shanghai Jingxin Industrial Development Co., Ltd.

[0205] The present disclosure provides a compound represented by formula (I) or an isomer thereof:

[0206]

[0207] In R4, select In the case of, the synthesis route of the compound of formula (I-1a) or the compound of formula (I-1b) or the compound of formula (I-1c) is as follows:

[0208]

[0209] Using the compound represented by formula (1) as the starting material, acetal reaction, electrophilic substitution reaction, and dehydroxylation protection reaction are sequentially performed to obtain a compound of formula (I-1a); the compound of formula (I-1a) is further subjected to a nucleophilic substitution reaction to obtain a compound of formula (I-1b); the compound of formula (I-1a) is further subjected to a condensation reaction to obtain a compound of formula (I-1c).

[0210] Preparation Example 1

[0211] In R4, select When p is selected from 1, q is selected from 0, and R3 is selected from H, formula (I-1a) NM041 Compound, formula (I-1b) NM041 Compound and formula (I-1c) NM041 The compound is shown below:

[0212]

[0213] Formula (I-1a) NM041 Compound, formula (I-1b)NM041 Compound and formula (I-1c) NM041 The synthetic route of the compound is as follows:

[0214]

[0215] (1-1) Formula (1) NM041 Synthesis of compounds

[0216] The synthetic route of the compound of formula (1) is as follows:

[0217]

[0218] The compound of formula (1-a) is used as a starting material, and is subjected to a hydrodehalogenation reaction and a hydrolysis reaction in sequence to obtain a compound of formula (1) NM041 Compound.

[0219] (1-1-1) Synthesis of the compound of formula (1-b)

[0220] The compound of formula (1-a) (25.0 g, 1.0 eq) was dissolved in 250 ml of toluene, heated to 110° C., tributyltin hydride (17.7 g, 1.0 eq) and azobisisobutyronitrile (1 g, 0.1 eq) were added, and the mixture was refluxed at 110° C. for 2 hours. After the reaction, the reaction solution was cooled to 25° C., ethyl acetate (100 ml) and potassium fluoride (10.59 g in 30 ml of water, 3.0 eq) were added, and the mixture was stirred at 25° C. for 2 hours. The reaction solution was filtered and the organic phase was separated. The aqueous phase was washed twice with 50 ml of ethyl acetate (50 ml×2), the organic phases were combined, the organic phases were washed once with 50 ml of saturated sodium chloride aqueous solution (50 ml×1), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the compound of formula (1-b) (18.7 g, yield 87.9%) as a light yellow oil. MS ESI (m / z) = 333.1 [M+H] + .

[0221] (1-1-2) Formula (1) NM041 Synthesis of compounds

[0222] The compound of formula (1-b) (18.7 g, 1 eq) was dissolved in anhydrous methanol (50 ml), sodium methoxide (0.288 g, 0.1 eq) was added, and the mixture was stirred at 25°C for 1 hour. After the reaction, the pH of the reaction solution was adjusted to 6-7 with a 4 mol / L hydrogen chloride 1,4-dioxane solution under ice bath, concentrated, condensed twice with acetonitrile, and then vacuum dried to obtain a white solid compound of formula (1): NM041 Compound (9.4 g, yield 100%).

[0223] (1-2) Formula (3) NM041Synthesis of compounds

[0224] Formula (1) NM041 The compound (9.4 g, 1.0 eq) was dissolved in 150 ml of acetonitrile, and the compound of formula (2) (30 ml, 3 eq, benzaldehyde dimethyl acetal) and DL-10-camphorsulfonic acid (1.5 g, 0.1 eq) were added respectively, stirred at 25°C for 5 hours, and 3 ml of triethylamine was added, and stirred at 25°C for 30 min. After the reaction was completed, the reaction solution was concentrated, 100 ml of water was added to the reaction solution, and then extracted twice with 100 ml of ethyl acetate (100 ml×2), the organic phases were combined, the organic phases were dried over anhydrous sodium sulfate and filtered, the organic phases were concentrated, and the organic phases were purified by column chromatography (eluent: ethyl acetate / petroleum ether=57 / 43, v / v) to obtain a white solid of formula (3) NM041 Compound (8.6 g, yield 59.5%). MS ESI (m / z) = 252.2 [M+H] + .

[0225] (1-3) Formula (5) NM041 Synthesis of compounds

[0226] The compound of formula (3) (4.3 g, 1.0 eq) was dissolved in 40 ml of DMF, sodium hydride (2.7 g, 4 eq) was added in an ice bath and reacted for 30 minutes in an ice bath, and the compound of formula (4) (8.1 g, 4 eq, 3-bromopropyne) was added, stirred at 25°C for 2 hours, and quenched by adding 20 ml of water. After the reaction was completed, the reaction solution was extracted 3 times with 50 ml of ethyl acetate (50 ml×3), the organic phases were combined, the organic phases were first washed 5 times with 20 ml of saturated sodium chloride solution (20 ml×5), then dried with anhydrous sodium sulfate, filtered, and concentrated to obtain a brown oil of formula (5): NM041 Compound (yield 100%). MS ESI (m / z) = 329.2 [M+H] + .

[0227] (1-4) Formula (I-1a) NM041 Synthesis of compounds

[0228] Formula (5) NM041 The compound (5.6 g, 1.0 eq) was dissolved in 30 ml of DCM, and 300 ml of 70 mass % acetic acid aqueous solution was added, and the mixture was reacted at 70° C. for 1 hour. After the reaction was completed, the reaction solution was directly concentrated to obtain a yellow oil of formula (I-1a): NM041 Compound (yield 100%). MS ESI (m / z) = 241 [M+H] + .

[0229] (1-5) Formula (I-1b) NM041 Synthesis of compounds

[0230] Formula (I-1a) NM041 The compound (5.6 g, 1.0 eq) was dissolved in 50 ml of pyridine, and the compound of formula (6) (10.2 g, 30.16 mmol, 1.3 eq, 4,4'-dimethoxytriphenylmethane, abbreviated as DMTrCl) was added under ice bath, and nitrogen was replaced 3 times, and stirred at 25°C for 3 hours, and 50 ml of methanol was added to quench. After the reaction was completed, the reaction solution was concentrated and 50 ml of water was added, and extracted with 50 ml of ethyl acetate 3 times (50 ml×3), and the organic phases were combined, dried with anhydrous sodium sulfate and filtered, concentrated, and purified by column chromatography (eluent: ethyl acetate / ether=16 / 84, v / v) to obtain a light yellow solid of formula (I-1b) NM041 Compound (5 g, yield 39.6%). MS ESI (m / z) = 543.1 [M+H] + .

[0231] (1-6) Formula (I-1c) NM041 Synthesis of compounds

[0232] Formula (I-1b) NM041 The compound (2.0 g, 1.5 eq) was dissolved in 20 ml of anhydrous dichloromethane, and 4,5-dicyanoimidazole (347.4 mg, 0.8 eq) and the compound of formula (7) (1.22 g, 1.1 eq, bis(diisopropylamino)(2-cyanoethoxy)phosphine) were added respectively, and the atmosphere was replaced with nitrogen three times, and stirred at 25°C for 2 hours. After the reaction was completed, 20 ml of saturated sodium bicarbonate solution was added to the reaction solution, and the mixture was extracted with 20 ml of dichloromethane three times (20 ml×3), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (C18 column, eluent: acetonitrile / water=72 / 28, v / v), and vacuum dried for 12 hours to obtain a white powder of formula (I-1c) NM041 Compound (2 g, yield 73.09%). MS ESI (m / z): 743.2 [M+H] + .

[0233] 1H NMR(400MHz, Acetonitrile-d3)δ7.53–7.47(m,2H),7.36(tt,J=9.6,3.4Hz,6H),7.28–7.22(m,1H),6.94–6 .86(m,4H),4.45(d,J=2.4Hz,1H),4.35(dt,J=6.1,1.9Hz,2H),4.18(ddd,J=11.2,5.4,2.6Hz,1H),3.81(s,7 H),3.79–3.20(m,8H),3.07(dt,J=10.5,7.0Hz,1H),2.79(q,J=2.6Hz,1H),2.72(dt,J=5.1,2.4Hz,1H),2.69 –2.63(m,1H),2.48–2.34(m,1H),2.17(d,J=1.0Hz,2H),1.08(dd,J=6.8,4.1Hz,10H),0.90(d,J=6.8Hz,2H).

[0234] Preparation Example 2

[0235] In R4, select When p is selected from 1, q is selected from 0, and R3 is selected from methoxy, formula (I-1a) NM064 Compound, formula (I-1b) NM064 Compound and formula (I-1c) NM064 The compound is shown below:

[0236]

[0237] Formula (I-1a) NM064 Compound, formula (I-1b) NM064 Compound and formula (I-1c) NM064 The synthetic route of the compound is as follows:

[0238]

[0239] (2-1) Formula (3) NM064 Synthesis of compounds

[0240] Formula (1) NM064The compound (13 g, 1.0 eq) was dissolved in 150 ml of acetonitrile, and the compound of formula (2) (30 ml, 3.0 eq, benzaldehyde dimethyl acetal) and DL-10-camphorsulfonic acid (1.5 g, 0.1 eq) were added respectively, stirred at 25°C for 5 hours, and 3 ml of triethylamine was added, and stirred at 25°C for 30 min. After the reaction was completed, the reaction solution was concentrated, 100 ml of water was added, and extracted twice with 100 ml of ethyl acetate (100 ml×2), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by normal phase purification column (eluent: ethyl acetate / petroleum ether=57 / 43, v / v) to obtain a white solid of formula (3) NM064 Compound (11.5 g, yield 60.8%). MS ESI (m / z) = 283 [M+H] + .

[0241] (2-2) Formula (5) NM064 Synthesis of compounds

[0242] Formula (3) NM064 The compound (5 g, 1.0 eq) was dissolved in 40 ml of N,N-dimethylformamide, sodium hydride (2.7 g, 4 eq) was added under ice bath, and the mixture was reacted for 30 minutes under ice bath, and the compound of formula (4) (8.1 g, 4 eq, 3-bromopropyne) was added, and the mixture was stirred at 25°C for 2 hours, and quenched by adding 20 ml of water. After the reaction was completed, the reaction solution was extracted 3 times with 50 ml of ethyl acetate (50 ml×3), the organic phases were combined, and the organic phases were washed 5 times with 20 ml of saturated sodium chloride solution (20 ml×5), and the organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a brown oil of formula (5): NM064 Compound (6.3 g, yield 100%). MS ESI (m / z) = 359 [M+H] + .

[0243] (2-3) Formula (I-1a) NM064 Synthesis of compounds

[0244] Formula (5) NM064 The compound (6.3 g, 17 mmol, 1.0 eq) was dissolved in 30 ml of dichloromethane, and 300 ml of 70 mass % acetic acid aqueous solution was added, and the mixture was reacted at 70°C for 1 hour. After the reaction was completed, the reaction solution was directly concentrated to obtain a yellow oil of formula (I-1a): NM064 Compound (4.78 g, yield 100%). MS ESI (m / z) = 271 [M+H] + .

[0245] (2-4) Formula (I-1b) NM064 Synthesis of compounds

[0246] Formula (I-1a)NM064 The compound (4.78 g, 17.7 mmol, 1.0 eq) was dissolved in 50 ml of pyridine, and the compound of formula (6) (7.8 g, 23.0 mmol, 1.3 eq, DMTrCl) was added under ice bath, and the atmosphere was replaced with nitrogen 3 times, stirred at 25°C for 3 hours, and quenched with 50 ml of methanol. After the reaction was completed, the reaction solution was concentrated, 50 ml of water was added, and extracted 3 times with 50 ml of ethyl acetate (50 ml×3), the organic phases were combined, dried over anhydrous sodium sulfate and filtered, concentrated, and purified by column chromatography (eluent: ethyl acetate / petroleum ether=16 / 84, v / v) to obtain a light yellow solid of formula (I-1b) NM064 Compound (6.7 g, yield 66.3%). MS ESI (m / z) = 573 [M+H] + .

[0247] (2-5) Formula (I-1c) NM064 Synthesis of compounds

[0248] Formula (I-1b) NM064 The compound (2.0 g, 1.0 eq) was dissolved in 20 ml of anhydrous dichloromethane, and DCI (330.4 mg, 0.8 eq, 4,5-dicyanoimidazole) and the compound of formula (7) (1.16 g, 1.1 eq, bis(diisopropylamino)(2-cyanoethoxy)phosphine) were added respectively, and the nitrogen was replaced 3 times, and stirred at 25°C for 2 hours. After the reaction was completed, 20 ml of saturated sodium bicarbonate aqueous solution was added to the reaction solution, and extracted 3 times with 20 ml of dichloromethane (20 ml×3), and the organic phases were combined, dried over anhydrous sodium sulfate and filtered, concentrated, and purified by column chromatography reverse phase (eluent: acetonitrile / water=72 / 28, v / v), and vacuum dried for 12 hours to obtain a white powder of formula (I-1c) NM064 Compound (2 g, yield 74.07%). MS ESI (m / z) = 774 [M+H] + .

[0249] 1H NMR(400MHz, DMSO-d6)δ7.45–7.39(d,J=7.8Hz,2H),7.36–7.18(tt,J=14.5,8.5Hz,7 H),6.95–6.84(d,J=7.5Hz,4H),5.01–4.96(s,1H),4.43–4.28(s,4H),3.81–3.70(s,8 H),3.65–3.35(m,12H),3.28–3.18(dt,J=14.5,7.2Hz,1H),3.06–2.97(t,J=9.5Hz,1 H),2.75–2.68(m,1H),1.07–0.95(q,J=7.4,6.8Hz,10H),0.84–0.78(d,J=6.6Hz,2H).

[0250] In R4, select In the case of, the synthetic route of the compound of formula (I-2) is as follows:

[0251]

[0252] The compound of formula (3) is used as the starting material, and is sequentially subjected to electrophilic substitution reaction, dehydroxylation protection reaction, nucleophilic substitution reaction and hydrolysis reaction to obtain the compound of formula (I-2).

[0253] Preparation Example 3

[0254] In R4, select When p is selected from 1, q is selected from 0, and R3 is selected from H, the synthetic route of the compound of formula (I-2) is as follows:

[0255]

[0256] (3-1) Synthesis of the compound of formula (9)

[0257] Formula (3) NM041The compound (4.3 g, 17.0 mmol, 1.0 eq) was dissolved in 50 ml of ultra-dry DMF, and NaH (2.7 g, 68 mmol, 4.0 eq) was added under ice bath and stirred for 1 hour; ethyl bromoacetate (5.7 g, 34 mmol, 2.0 eq, CAS No. 105-36-2) and KI (4.3 g, 25.9 mmol, 1.5 eq) were added and reacted at 25°C for 3 hours, and saturated aqueous ammonium chloride solution was added to quench. After the reaction was completed, 20 ml of water was added to the reaction solution, and the mixture was extracted 3 times with 50 ml of ethyl acetate (50 ml×3), the organic phases were combined, and the organic phases were washed 10 times with 20 ml of saturated aqueous sodium chloride solution (20 ml×10), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a dark brown oily compound of formula (9), which was used directly in the next step. MS ESI (m / z)=425.2[M+H] + .

[0258] (3-2) Synthesis of the compound of formula (10)

[0259] The compound of formula (9) (5 g, 1.0 eq) was dissolved in 30 ml of dichloromethane, and 300 ml of 70 mass % glacial acetic acid aqueous solution was added, and stirred at 50°C for 2 hours. After the reaction was completed, the reaction solution was directly concentrated to obtain a dark brown oily compound of formula (10), which was directly used in the next step. MS ESI (m / z) = 337 [M+H] + .

[0260] (3-3) Synthesis of the compound of formula (11)

[0261] The compound of formula (10) (3.2 g, 9.52 mmol, 1.0 eq) was dissolved in 70 ml of pyridine, and the compound of formula (6) (4.19 g, 12.4 mmol, 1.3 eq, DMTrCl) was added under ice bath, stirred at 25°C for 3 hours, and quenched by adding 30 ml of methanol. After the reaction was completed, the reaction solution was concentrated, 20 ml of water was added, and extracted with 50 ml of ethyl acetate 3 times (50 ml×3), the organic phases were combined, dried over anhydrous sodium sulfate and filtered, concentrated, and purified by column chromatography (C18 column, eluent: acetonitrile / water=52 / 48, v / v) to obtain the compound of formula (11) (5 g, yield 83%) as a yellow solid. MS ESI (m / z)=639[M+H] + .

[0262] (3-4) Synthesis of the compound of formula (I-2)

[0263] The compound of formula (11) (2 g, 3.16 mmol, 1.0 eq) was dissolved in 10 ml of methanol, and an aqueous solution of NaOH (6.3 ml, 1 mol / L) was added, and stirred at 25°C for 1 hour. After the reaction was completed, the pH of the reaction solution was adjusted to neutral with hydrochloric acid, the reaction solution was filtered, the filtrate was concentrated, and column chromatography was performed for reverse phase purification (C18 column, eluent: acetonitrile / water = 26 / 74, v / v) to obtain a light yellow solid compound of formula (I-2) (920 mg, yield 51%). MS ESI (m / z) = 583 [M+H] + .

[0264] Preparation Example 4: Synthesis of compounds CR01022 and CR01022Z (a cluster of CR01022, denoted as (CR01022)×1)

[0265] In this preparation example, the synthetic routes of compounds CR01022 and CR01022Z are as follows:

[0266]

[0267] (4-1) Synthesis of Compound NM015

[0268]

[0269] Compound NM015-1 (5 g, 1.1 eq.) and D-galactosamine pentaacetate (8.07 g, 1.0 eq.) were added to 96 ml of dichloroethane, and the temperature was raised to 85°C. Scandium trifluoromethanesulfonate (0.38 g, 0.77 mmol) was added in batches at 85°C, and the mixture was stirred at 85°C for 3 hours. 16 ml of triethylamine was added to quench the mixture. After the reaction was completed, the reaction system was cooled to 25°C, 100 ml of water and 100 ml of dichloromethane were added to the reaction solution, and the mixture was filtered to separate the organic phase. The organic phase was dried over anhydrous sodium sulfate and filtered, concentrated, and purified by column chromatography (C18 column, eluent: acetonitrile / water = 72 / 28, v / v) to obtain an oily compound NM015 (6.6 g). ESI-MS (m / z) = 549 [M+H] + .

[0270] (4-2) Synthesis of Compound CR01022-1

[0271] Compound NM015 (1114 mg, 2.03 mmol, 2.2 eq.), formula (I-1b) NM041Compound (500 mg, 0.922 mmol, 1.0 eq.), cuprous iodide (701 mg, 3.69 mmol, 4.0 eq.), N,N-diisopropylethylamine (476 mg, 3.69 mmol, 4.0 eq.) were added to 3 ml of N,N-dimethylformamide and stirred at 25°C for 1.5 hours. After the reaction was completed, 5 ml of ethyl acetate and 5 ml of water were added to the reaction solution, filtered and the organic phase was separated, and the organic phase was dried over anhydrous sodium sulfate and filtered, concentrated, and purified by column chromatography (C18 column, eluent: acetonitrile / water = 72 / 28, v / v) to obtain foamy compound CR01022-1 (1 g). ESI-MS (m / z) = 1639 [M+H] + .

[0272] (4-3) Synthesis of Compound CR01022

[0273] Compound CR01022-1 (850 mg, 0.523 mmol, 1.0 eq.) was added to 17 ml of dichloromethane, and bis(diisopropylamino)(2-cyanoethoxy)phosphine (313 mg, 1.04 mmol, 2.0 eq.) was added in batches, and then 4,5-dicyanoimidazole (49 mg, 0.415 mmol, 0.8 eq.) was added, and nitrogen was replaced 3 times, and stirred at 25°C for 1 hour. After the reaction was completed, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution for washing once, and the organic phase was separated, concentrated, and purified by column chromatography (C18 column, acetonitrile / water=72 / 28, v / v) to obtain compound CR01022 (560 mg). MS ESI (m / z)=1839[M+H] + .

[0274] (4-4) Synthesis of Compound CR01022Z

[0275] Compound CR01022-1 (160 mg, 0.1 mmol, 1.0 eq.) was added to 3.2 ml of dichloromethane, succinic anhydride (18 mg, 0.18 mmol, 1.8 eq.), 4-dimethylaminopyridine (1.2 mg, 0.01 mmol, 0.01 eq.) and triethylamine (19.7 mg, 0.2 mmol, 2.0 eq.) were added to a 25 ml reaction kettle, and nitrogen was replaced three times, and stirred at 25° C. for 16 hours. After the reaction was completed, column chromatography reverse phase purification (C18 column, acetonitrile / water = 72 / 28) was performed to obtain an intermediate product (100 mg).

[0276] The above intermediate product (100 mg, 0.058 mmol, 1.0 eq.), amino CPG (1.44 g, 0.115 mmol, 80 umol / g), benzotriazole-N, N, N', N'-tetramethyluronium hexafluorophosphate (32.67 mg, 0.086 mmol, 1.5 eq.) and N, N-diisopropylethylamine (14.8 mg, 0.115 mmol, 2.0 eq.) were mixed, shaken for 16 hours, the reaction solution was filtered, the solid was washed once with 10 ml of acetonitrile and vacuum dried. The solid was mixed with 4-dimethylaminopyridine (2 mg, 0.017 mmol), Cap1 (15 ml) and Cap2 (1.5 ml), shaken for 6 hours, the reaction solution was filtered, the filter cake was washed once with 10 ml of acetonitrile and vacuum dried to obtain compound CR01022Z (1.366 g, loading 20-30 umol / g).

[0277] Wherein, Cap1 and Cap2 are capping reagent solutions, Cap1 is a 20 volume % N-methylimidazole mixed solution in pyridine / acetonitrile, and the volume ratio of pyridine to acetonitrile is 3:5; Cap2 is a 20 volume % acetic anhydride acetonitrile solution.

[0278] Preparation Example 5: Compound CR01027 and compound CR01027Z (a cluster of CR01027, denoted as (CR01027)×1) synthesis

[0279] In this preparation example, the synthesis process of compound CR01027 and compound CR01027Z is as follows:

[0280]

[0281] (5-1) Synthesis of Compound CR01027-1

[0282] Compound NM015 (1125 mg, 2.03 mmol, 2.2 eq.), formula (I-1b) NM064 Compound (500 mg, 0.922 mmol, 1.0 eq.), cuprous iodide (701 mg, 3.69 mmol, 4.0 eq.), N,N-diisopropylethylamine (476 mg, 3.69 mmol, 4.0 eq.) were added to 3 ml of N,N-dimethylformamide and stirred at 25°C for 1.5 hours. After the reaction was completed, 5 ml of ethyl acetate and 5 ml of water were added to the reaction solution, filtered, and the organic phase was separated. The organic phase was dried over anhydrous sodium sulfate and concentrated, and purified by column chromatography (C18 column, acetonitrile / water = 72 / 28, v / v) to obtain a foamy compound CR01027-1 (1 g, yield 68.5%). ESI-MS (m / z): 1669.7 [M+H] + .

[0283] (5-2) Synthesis of Compound CR01027

[0284] Compound CR01027-1 (870 mg, 0.530 mmol, 1.0 eq.) was added to 20 ml of dichloromethane, and bis(diisopropylamino)(2-cyanoethoxy)phosphine (330 mg, 1.04 mmol, 2.0 eq.) was added in batches, and then 4,5-dicyanoimidazole (52 mg, 0.415 mmol, 0.8 eq.) was added, and nitrogen was replaced 3 times, and stirred at 25°C for 1 hour. After the reaction was completed, the reaction solution was washed once with sodium bicarbonate aqueous solution, and the organic phase was separated, concentrated, and purified by column chromatography (C18 column, acetonitrile / water=72 / 28, v / v) to obtain compound CR01027 (560 mg, yield 60.8%). MS ESI (m / z) = 1869.8 [M+H] + .

[0285] (5-3) Synthesis of Compound CR01027Z

[0286] Compound CR01027Z was prepared according to the synthetic method of compound CR01022Z (4-4) in Preparation Example 4.

[0287] Preparation Example 6: Compound CR01017 and compound CR01017Z (a cluster of CR01017, denoted as (CR01027)×1) synthesis

[0288] In this preparation example, the synthesis process of compound CR01017 and compound CR01017Z is as follows:

[0289]

[0290] (6-1) Synthesis of Compound CR01017-1

[0291] The compound of formula (I-2) (900 mg, 1.55 mmol, 1 eq), (2R, 3R, 4R, 5R, 6R)-5-acetylamino-2-(acetoxymethyl)-6-(2-(2-(aminoethoxy)ethoxy) (2.02 g, 3.88 mmol, 2.5 eq) and HATU (1.35 g, 3.56 mmol, 2.3 eq) were dissolved in 25 ml of N,N-dimethylformamide, DIEA (800 mg, 6.2 mmol, 4.0 eq) was added under ice bath, and stirred at 25° C. for 12 hours. After the reaction was completed, column chromatography was performed for reverse phase purification (C18 column, eluent: acetonitrile / water=20 / 80, v / v) to obtain compound CR01017-1 (700 mg, yield 28.6%) as a white solid. MS ESI (m / z)=1591.2 [M+H] + .

[0292] (6-2) Synthesis of Compound CR01017

[0293] Compound CR01017 (500 mg, 0.31 mmol, 1.0 eq), 4,5-dicyanoimidazole (30 mg, 0.25 mmol, 0.8 eq) and bis(diisopropylamino)(2-cyanoethoxy)phosphine (138 mg, 0.46 mmol, 1.5 eq) were dissolved in 10 ml of ultra-dry dichloromethane and reacted at 25° C. for 2 hours in a nitrogen atmosphere. After the reaction was completed, the reaction solution was washed twice with 10 ml of saturated sodium bicarbonate (10 ml×2), the organic phase was concentrated, and column chromatography was performed for reverse phase purification (C18 column, eluent: acetonitrile / water=80 / 20, v / v) to obtain compound CR01017 (480 mg, yield 83.1%) as a white solid. MS ESI (m / z)=1791.2[M+H] + .

[0294] (6-3) Synthesis of Compound CR01017-2

[0295] Compound CR01017-1 (200 mg, 0.13 mmol, 1.0 eq) was dissolved in 10 ml of dichloromethane, succinic anhydride (14 mg, 0.14 mmol, 1.1 eq) and triethylamine (26 mg, 0.26 mmol, 2.0 eq) were added, and stirred at 25°C for 12 hours. After the reaction was completed, the reaction solution was concentrated and purified by column chromatography (C18 column, eluent: acetonitrile / water = 36 / 64, v / v) to obtain compound CR01017-2 (150 mg, yield 71.4%) as a white solid. MS ESI (m / z) = 1691.2 [M+H] + .

[0296] (6-4) Synthesis of Compound CR01017Z

[0297] Compound CR01017-2 (70 mg, 0.041 mmol, 1.0 eq), benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (22 mg, 0.062 mmol, 1.5 eq, abbreviated as HBTU), and N,N-diisopropylethylamine (10 mg, 0.082 mmol, 2.0 eq) were dissolved in 10 ml of acetonitrile, stirred at 25°C for 5 minutes, aminoCPG (970 mg, 80 umol / g) was added, and the mixture was reacted on a shaking table at 25°C for 18 hours. The mixture was filtered, and the filter cake was washed twice with 10 ml of dichloromethane (10 ml×2) and then washed twice with 10 ml of acetonitrile (10 ml×2). The filter cake, DMAP (3 mg, 0.024 mmol), Cap1 (10 ml) and Cap2 (1 ml) were mixed, reacted on a shaking table at 25°C for 5 hours, filtered, and the filter cake was rinsed three times with 10 ml of acetonitrile and dried to obtain compound CR01017Z (720 mg).

[0298] Wherein, Cap1 and Cap2 are capping reagent solutions, Cap1 is a 20 volume % N-methylimidazole mixed solution in pyridine / acetonitrile, and the volume ratio of pyridine to acetonitrile is 3:5; Cap2 is a 20 volume % acetic anhydride acetonitrile solution.

[0299] Preparation Example 9: Synthesis of Reference Compound NM042

[0300] In this preparation example, the synthesis process of compound NM042 is as follows:

[0301]

[0302] (7-1) Synthesis of Compound NM042-2

[0303] Compound NM042-1 (5.0 g, 1.0 eq.) and sodium hydride (3.78 g, 2.5 eq.) were added to 60 ml of DMF, cooled to 0°C, stirred at 0°C for 0.5 hours, and propargyl bromide (9.0 g, 2.0 eq.) was slowly added during stirring, and stirred at 25°C for 4 hours. After the reaction was completed, 100 ml of water was added to the reaction solution, and the mixture was extracted three times with ethyl acetate (3×100 ml), the organic phases were combined, washed once with 100 ml of saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain oily compound NM042-2 (9.0 g). ESI-MS (m / z) = 171 [M+H] + .

[0304] (7-2) Synthesis of Compound NM042-3

[0305] Compound NM042-2 (9.0 g, 37.8 mmol) and Amberlyst-15 resin (13.5 g, 150% w / w) were added to 180 ml of methanol, replaced with nitrogen three times, and stirred at 25°C for 6 hours. After the reaction was completed, the reaction solution was filtered and concentrated to obtain an oily compound NM042-3 (9.1 g). ESI-MS (m / z) = 131.2 [M+H] + .

[0306] (7-3) Synthesis of Compound NM042-4

[0307] Compound NM042-3 (5 g, 1.0 eq.) was added to 75 ml of pyridine solution, cooled to 0°C, DMTrCl (16.9 g, 1.69 eq.) was added in batches at 0°C, and stirred at 25°C for 3 hours. After the reaction was completed, the reaction solution was concentrated and purified by column chromatography (C18 column, eluent: acetonitrile / water = 72 / 28, v / v) to obtain compound NM042-4 (15 g, yield 90.4%). ESI-MS (m / z) = 433.2 [M+H] + .

[0308] (7-4) Synthesis of Compound NM042

[0309] Compound NM042-4 (2.5 g, 1.0 eq.), bis(diisopropylamino)(2-cyanoethoxy)phosphine (3.5 g, 2.0 eq.), and DCI (0.567 g, 0.8 eq.) were added to 50 ml of DCM and stirred for 3 hours under nitrogen protection. After the reaction was completed, 50 ml of saturated sodium bicarbonate solution was added to the reaction solution for washing once, and the organic phase was separated. The organic phase was washed once with 50 ml of saturated brine, dried with anhydrous sodium sulfate, filtered, concentrated, and separated by reverse phase HPLC to obtain compound NM042 (2.0 g, yield 56%) as a white oil. ESI-MS (m / z): 619.3 [M+H] + .

[0310] 1 H NMR(400MHz, DMSO-d6)δ0.97–1.04(d,J=6.7Hz,3H),1.06–1.20(m,9H),3.05–3.14(dd,J=5.5,10.7Hz,2H),3.46–3.69(m,6H),3.70–3 .75(d,J=2.5Hz,7H),3.98–4.09(dt,J=4.9,10.3Hz,1H),4.09–4.17(m,2H),6.81–6.93(m,4H),7.15–7.34(m,7H),7.35–7.46(m,2H).

[0311] Preparation Example 10: Synthesis of Reference Compound CR01023 and Compound CR01023Z

[0312] In this preparation example, the synthesis process of compound CR01023 and compound CR01023Z is as follows:

[0313]

[0314] (8-1) Synthesis of Compound CR01023-1

[0315] Compound NM015 (2.79 g, 5.08 mmol, 2.2 eq.), compound NM042-4 (1.0 g, 2.31 mmol, 1.0 eq.), cuprous iodide (1.76 g, 9.24 mmol, 4.0 eq.), N,N-diisopropylethylamine (1.19 g, 9.24 mmol, 4.0 eq.) were added to 10 ml of N,N-dimethylformamide, stirred at 25°C for 1.5 hours, 15 ml of ethyl acetate and 15 ml of water were added, filtered, separated, the organic phase was dried over anhydrous sodium sulfate and filtered, concentrated, and purified by column chromatography (C18 column, acetonitrile / water = 72 / 28, v / v) to obtain foamy compound CR01023-1 (1.6 g, yield 70.5%). ESI-MS (m / z) = 980.2 [M+H] + .

[0316] (8-2) Synthesis of Compound CR01023

[0317] Compound CR01023-1 (1.0 g, 1.02 mmol, 1.0 eq.) was added to 20 ml of dichloromethane, and bis(diisopropylamino)(2-cyanoethoxy)phosphine (0.61 g, 2.04 mmol, 2.0 eq.) was added in batches, and then 4,5-dicyanoimidazole (96 mg, 0.82 mmol, 0.8 eq.) was added, and nitrogen was replaced 3 times, and stirred at 25°C for 1 hour. After the reaction was completed, sodium bicarbonate aqueous solution was added to the reaction solution for washing once, and the organic phase was separated, concentrated, and purified by column chromatography (C18 column, acetonitrile / water=72 / 28, v / v) to obtain compound CR01023 (880 mg, yield 73.3%). MS ESI (m / z) = 1181.5 [M+H] + .

[0318] (8-3) Synthesis of Compound CR01023Z

[0319] Compound CR01023Z was prepared according to the synthetic method of compound CR01022Z (4-4) in Preparation Example 4.

[0320] Reference compound L96-PS

[0321] Compound L96-PS was purchased from Agilent Pharmaceuticals (Tianjin) Co., Ltd. with a loading of 120±12 μmol / g (detection method: UV / HPLC).

[0322] The structural formula of the reference compound L96-PS is as follows:

[0323]

[0324] Wherein, PS represents polystyrene resin solid phase carrier.

[0325] Preparation Example 9: Synthesis Method 1 of siRNA Conjugate

[0326] (9-1) Synthesis of the positive strand (SS)

[0327] By the method of phosphoramidite nucleic acid solid phase synthesis, the above compounds connected to the solid phase carrier (i.e., CR01022Z, CR01023Z, CR01027Z, L96-PS) are used to start the cycle, and the nucleoside monomers are connected one by one in the 3'-5' direction according to the nucleotide sequence (compounds CR01022, CR01023 and CR01027 can be regarded as a nucleoside monomer respectively). Each connection of a nucleoside monomer includes four steps of deprotection, coupling, capping, oxidation or sulfurization. The synthesis conditions are given as follows:

[0328] The nucleoside monomer was prepared into an acetonitrile solution with a concentration of 0.1 M.

[0329] The conditions of the deprotection reaction in each step are the same. The conditions of the deprotection reaction are: temperature of 25° C., reaction time of 70 seconds, deprotection reagent of dichloroacetic acid in dichloromethane solution (3% by volume), and the molar ratio of dichloroacetic acid to 4,4'-dimethoxytrityl protecting group on the solid phase carrier is 5:1.

[0330] The conditions of each coupling reaction are the same. The coupling reaction conditions are: temperature is 25°C, the molar ratio of the nucleic acid sequence connected to the solid phase support to the nucleoside monomer is 1:10, the molar ratio of the nucleic acid sequence connected to the solid phase support to the coupling reagent is 1:65, the reaction time is 600 seconds, the coupling reagent is an acetonitrile solution of 5-ethylthio-1H-tetrazole with a concentration of 0.5M, and the thiolation reagent is an acetonitrile / pyridine mixed solution of hydrogenated xanthanol with a concentration of 0.2M (the volume ratio of acetonitrile and pyridine is 1:1).

[0331] The conditions of each capping reaction are the same. The conditions of the capping reaction are: temperature is 25°C; reaction time is 2 minutes; the capping reagent solution is a mixed solution of Cap1 and Cap2 with a molar ratio of 1:1, Cap1 is a pyridine / acetonitrile mixed solution of N-methylimidazole with a concentration of 20 volume%, the volume ratio of pyridine to acetonitrile is 3:5, Cap2 is an acetonitrile solution of acetic anhydride with a volume ratio of 20 volume%; the molar ratio of N-methylimidazole in Cap1 capping reagent, acetic anhydride in Cap2 capping reagent to the nucleic acid sequence connected to the solid phase carrier is 1:1:1.

[0332] The conditions for each step of the oxidation reaction are the same. The conditions for the oxidation reaction are: temperature of 25°C; reaction time of 3 seconds; oxidation reagent concentration of 0.05M iodine water, the molar ratio of iodine to the nucleic acid sequence connected to the solid phase carrier in the coupling reaction is 30:1; oxidation reaction is carried out in a water / pyridine mixed solvent (the volume ratio of water to pyridine is 1:9). The conditions for the sulfidation reaction are: temperature of 25°C; reaction time of 360 seconds; thiolation reagent concentration of 0.2M hydrogenated xanthan gum pyridine solution, the molar ratio of thiolation reagent to the nucleic acid sequence connected to the solid phase carrier in the coupling reaction is 4:1; thiolation reaction is carried out in a water / pyridine mixed solvent (the volume ratio of water to pyridine is 1:9).

[0333] After the last nucleoside monomer is connected, the nucleic acid sequence connected to the solid phase carrier is cut, deprotected, purified, desalted, and then freeze-dried to obtain the positive chain, wherein:

[0334] The cleavage and deprotection conditions are as follows: the synthesized nucleotide sequence connected to the solid phase carrier is added to 25% by mass ammonia water, the amount of ammonia water is 0.5 ml / μmol, the reaction is carried out at 55°C for 16 hours, the solvent is removed, and the product is concentrated to dryness in vacuo. After the ammonia water treatment, the product is dissolved with 0.4 ml / μmol N-methylpyrrolidone relative to the amount of single-stranded nucleic acid, and then 0.3 ml / μmol triethylamine and 0.6 ml / μmol triethylamine trihydrofluoride are added to remove the 2'-O-TBDMS protection on the ribose.

[0335] Purification and desalting conditions: The nucleic acid was purified by gradient elution of NaCl using a preparative ion chromatography purification column (Source 15Q). Specifically, eluent 1 was 20 mM sodium phosphate (pH = 8.1), and the solvent was a water / acetonitrile mixed solution (the volume ratio of water to acetonitrile was 9:1); eluent 2 was 1.5 M sodium chloride, 20 mM sodium phosphate (pH = 8.1), and the solvent was a water / acetonitrile mixed solution (the volume ratio of water to acetonitrile was 9:1); the elution gradient was eluent 1: eluent 2 = (100:0)-(50:50). The product eluates were collected and combined, and desalted using a reverse chromatography purification column. The desalting conditions included desalting using a dextran gel column, the filler was dextran gel G25, and eluted with deionized water.

[0336] Detection: Use ion exchange chromatography (IEX-HPLC) for purity detection; use liquid chromatography-mass spectrometry (LC-MS, Liquid ChromatogRLhy-Mass SP1ectrometry, purchased from Waters, model: LCTPremier) for molecular weight detection, and compare the measured value of the molecular weight with the theoretical value. If the measured value is consistent with the theoretical value, it indicates that the compound is conjugated to the 3' end of the siRNA sense chain.

[0337] During the synthesis of the sense strand, the following targeting ligands (carriers) were synthesized:

[0338] The structural formula of the two clusters of CR01017 (denoted as (CR01017)×2) is:

[0339]

[0340] The structural formula of the two clusters of CR01022 (denoted as (CR01022)×2) is:

[0341]

[0342] The structural formula of three clusters of CR01022 (denoted as (CR01022)×3) is:

[0343]

[0344] The structural formula of three clusters of CR01023 (denoted as (CR01023)×3) is:

[0345]

[0346] The structural formula of the two clusters of CR01027 (denoted as (CR01027)×2) is:

[0347]

[0348] (9-2) Synthesis of antisense strand (AS)

[0349] The antisense chain was synthesized using a universal solid phase carrier. The deprotection, coupling, capping, oxidation or sulfurization reaction conditions, cleavage and deprotection conditions, purification and desalting conditions in the solid phase synthesis method of the antisense chain are the same as those in step (9-1) for synthesizing the sense chain.

[0350] Detection: Use ion exchange chromatography (IEX-HPLC) for purity detection; use liquid chromatography-mass spectrometry (LC-MS, Liquid Chromatogram Hy-Mass Spectrometry, purchased from Waters, model: LCT Premier) for molecular weight detection, and compare the measured value of the molecular weight with the theoretical value. If the measured value is consistent with the theoretical value, it indicates that the siRNA antisense chain is obtained.

[0351] (9-3) Synthesis of siRNA conjugates

[0352] The sense chain synthesized in step (9-1) and the antisense chain synthesized in step (9-2) are mixed in an equimolar ratio, dissolved in water for injection and heated to 95°C, slowly cooled to room temperature and kept at room temperature for 10 minutes, so that the sense chain and the antisense chain form a double-stranded structure through hydrogen bonds, thereby obtaining the target designed siRNA conjugate.

[0353] After each siRNA conjugate was diluted to a concentration of 0.2 mg / ml (based on siRNA) using ultrapure water (Milli-Q ultrapure water instrument, resistivity 18.2 MΩ*cm (25°C)), the molecular weight was detected using a liquid chromatography-mass spectrometer (LC-MS, Liquid ChromatogRLhy-MassSpectrometry, purchased from Waters, model: LCT Premier). If the measured value is consistent with the theoretical value, it means that the synthesized conjugate is the double-stranded nucleic acid sequence of the target design.

[0354] Preparation Example 10: Synthesis Method 2 of siRNA Conjugate

[0355] In this preparation example, siRNA, linker groups (IC-NM041 and NM042) and ligand groups (NM015) are sequentially connected to form a siRNA conjugate.

[0356] Taking the linker group IC-NM041 and the ligand group NM015 as an example, the synthesis route of the siRNA conjugate is as follows:

[0357]

[0358] (10-1) Synthesis of the positive strand (SS)

[0359] Specifically, the method for preparing the sense strand includes the following steps:

[0360] S1, Formula (I-1c) NM041 The compound is regarded as a nucleoside monomer, and the formula (I-1c) is synthesized by phosphoramidite solid phase method. NM041 The compound is connected to a solid phase carrier, and then the nucleoside monomers are connected one by one in the direction from 3' to 5' according to the nucleotide type and order of the sense strand of the above siRNA sequence. The connection of each nucleoside monomer includes four steps of deprotection, coupling, capping, oxidation or sulfurization. The deprotection, coupling, capping, oxidation or sulfurization reaction conditions in the synthesis of the sense strand are the same as those in step (9-1) of Preparation Example 9 for synthesizing the sense strand.

[0361] The sense strand hemiconjugate containing the linker group (denoted as SS-(NM041)×2) was separated, wherein the linker group NM041 was connected to the 3' end of the sense strand of the siRNA.

[0362] Specifically, the method for preparing the sense strand includes the following steps:

[0363] Step 1: Mix 150 μL of H2O, 70 μL of 0.2 mol / L carbonate buffer solution (pH = 9.2) and 70 μL of N,N-dimethylformamide (DMF) to obtain a mixed solvent; dissolve SS-(NM041)×2 in the mixed solvent to obtain a SS-(NM041)×2 solution with a concentration of 1.0 eq.

[0364] Step 2: Dissolve 6.0 eq of ligand compound NM015 in 70 μL of DMF to obtain NM015 solution.

[0365] Step 3: Mix the SS-(NM041)×2 solution obtained in step 1 and the NM015 solution obtained in step 2 to obtain a reactant mixture.

[0366] Step 4: Take 10.0 eq of tris(3-hydroxypropyltriazolylmethyl)amine (THPTA) and 3.0 eq of CuSO4·5H2O in a volume ratio of THPTA:CuSO4·5H2O=10:3, mix them, shake them at 40°C for 5 min, take 37 μL and add it to the reactant mixture obtained in the above step 3, and vortex shake to obtain an intermediate product mixture, and measure the pH of the intermediate product mixture to be 8.

[0367] Step 5: Take 25.0 eq of sodium ascorbate and quickly add it to the intermediate product mixture obtained in step 4, and vortex it for oscillation. React it at 40° C. for 1 h to obtain a product mixture.

[0368] Step 6, purification: Take 3 μL of the product mixture obtained in step S3, dilute the product mixture with a mixed solution of DMF and H2O (the volume ratio of DMF and H2O is 1:5), and then separate and purify it by HPLC. The chromatographic column used in the HPLC treatment process is a C18 chromatographic column, the mobile phase is an ammonium bicarbonate buffer solution, and a gradient elution method is adopted. The product after HPLC treatment and purification is freeze-dried.

[0369] (10-2) Synthesis of antisense strand (AS):

[0370] Prepared according to the synthesis method of the antisense chain (AS) in Preparation Example 9 (9-2).

[0371] (10-3) Synthesis of siRNA conjugates:

[0372] Prepared according to the synthesis method of siRNA conjugate (9-3) in Preparation Example 9.

[0373] In the two methods for synthesizing siRNA conjugates provided in the present disclosure, the first method for synthesizing the siRNA conjugate is to first synthesize the carrier, then synthesize the sense chain conjugate, and finally synthesize the siRNA conjugate; the second method for synthesizing the siRNA conjugate is to first synthesize the sense chain half conjugate, then synthesize the sense chain conjugate, and finally synthesize the siRNA conjugate.

[0374] Among them, when synthesizing the same amount of siRNA conjugates, compared with synthesis method 2, synthesis method 1 uses less raw materials in synthesizing the carrier, but takes longer to synthesize the siRNA conjugate; compared with synthesis method 1, synthesis method 2 takes less time to synthesize the siRNA conjugate, but uses more raw materials in synthesizing the carrier.

[0375] When the vector is a cluster of CR01017, the structural formula of the siRNA conjugate is as follows:

[0376]

[0377]

[0378] When the vector is two clusters of CR01017, the structural formula of the siRNA conjugate is as follows:

[0379]

[0380] When the carrier is a cluster of CR01022, the structural formula of the siRNA conjugate is:

[0381] When the carrier is two clusters of CR01022, the structural formula of the siRNA conjugate is:

[0382]

[0383] When the vector is three clusters of CR01022, the structural formula of the siRNA conjugate is:

[0384]

[0385] When the vector is three clusters of CR01023, the structural formula of the siRNA conjugate is:

[0386]

[0387] When the carrier is two clusters of CR01027, the structural formula of the siRNA conjugate is:

[0388]

[0389] When the carrier is L96, the structural formula of the siRNA conjugate is:

[0390]

[0391] in, Represents siRNA.

[0392] The present invention synthesized the siRNA conjugates in Table 3 according to the methods of Preparation Example 9 and Preparation Example 10, respectively.

[0393] In the present disclosure, the conjugates RZ599001 and RZ502031 can only be synthesized using the synthesis method 1 of the siRNA conjugate described in Preparation Example 9.

[0394] Conjugates RZ899040, RZ899011, RZ899009, RZ899048, RZ802010, RZ802011, RZ899041, RZ899042, and RZ899038 can be synthesized by either the synthesis method 1 of the siRNA conjugates described in Preparation Example 9 or the synthesis method 2 of the siRNA conjugates described in Preparation Example 10. Specifically, conjugates RZ899040, RZ899011, RZ899009, and RZ802010 are synthesized by the synthesis method 1 of the siRNA conjugates described in Preparation Example 9; and conjugates RZ899048, RZ802011, RZ899041, RZ899042, and RZ899038 are synthesized by the synthesis method 2 of the siRNA conjugates described in Preparation Example 10.

[0395] UmsUmsUmUmAmAmUfCfCfUmCmAmCmUmCmUmAmAmAm, as shown in SEQ ID No.1;

[0396] UmsUfsUmAmGmAfGmUmGmAmGmGmAmUfUmAfAmAmAmsUmsGm, as shown in SEQ ID No.2;

[0397] CmsAmsGmAmCmAmGfAfCfAmAmGmAmCmCmAmUmCmUm, as shown in SEQ ID No.3;

[0398] AmsGfsAmUmGmGfUmCmUmUmGmUmCmUfGmUfCmUmGmsGmsAm, as shown in SEQ ID No.4SEQID No.3.

[0399] Table 3 siRNA conjugates

[0400]

[0401]

[0402] Unless otherwise specified, the base composition and modification meanings described in the embodiments of the present disclosure are as follows: capital letters A, U, G, C, and T represent the base composition of the nucleotides; the lowercase letter m represents that the nucleotide represented by the previous letter is a methoxy-modified nucleotide; the lowercase letter f represents that the nucleotide represented by the previous letter is a fluorinated-modified nucleotide; the lowercase letter s represents that the nucleotides represented by the two letters before and after it are connected by a thiophosphate bond.

[0403] In the context of this application and this disclosure, unless otherwise specified, the siRNA sequences used in this application and this disclosure were commissioned to Suzhou Beixin Biotechnology Co., Ltd. for synthesis; the PCR primers used in this application and this disclosure were commissioned to Beijing Qingke Biotechnology Co., Ltd. for synthesis; the experimental animals C57BL / 6J mice used in this application and this disclosure were purchased from Sibeifu (Beijing) Biotechnology Co., Ltd.

[0404] Table 4 Detection results of siRNA conjugates

[0405]

[0406]

[0407] It can be seen from the data in Table 4 that the sense strand (SS) and the antisense strand (AS) can be well connected to the ligand with a high purity.

[0408] General Experiments

[0409] Method for evaluating target gene inhibitory activity in mice

[0410] 6-8 week old C57BL / 6J mice were randomly divided into groups according to body weight (all female). The mice in each group were given a single dose of drug according to body weight, and each siRNA conjugate was configured into a corresponding concentration (calculated as siRNA) solution for administration with a PBS solution, and the administration volume was 5ml / kg mouse body weight (calculated as siRNA). The PBS control group was given the same volume of PBS solution (without drug conjugate). The day of administration was recorded as the first day (recorded as D1), and at the preset time after administration, 5 mice were killed in each group. The mice killed were grossly dissected and the liver tissue of each mouse killed was collected, and the liver tissue was cut into small pieces of about 2mm3 and preserved with RNA Later.

[0411] Liver tissue samples at different time points in different experimental groups were taken from the above RNA later, and the liver tissue samples were broken in a Tissuelyser II fully automatic tissue homogenizer for 60 seconds, and then total RNA was extracted using a fully automatic nucleic acid extractor (purchased from Zhejiang Hanwei Technology Co., Ltd.) and a nucleic acid extraction kit (purchased from Zhejiang Hanwei Technology Co., Ltd.) according to the standard operating procedures for total RNA extraction.

[0412] Take the above 1 μg total RNA, use the reverse transcription kit (Promega, Reverse Transcription System, A3500) and select Oligo (dT) 15 reverse transcription primer, prepare 20 μL reverse transcription system according to the method described in the reverse transcription kit manual and complete the reverse transcription reaction. After the reaction is completed, add 80 μL RNase-Free water to the reverse transcription system to obtain cDNA solution. Then use the real-time fluorescence quantitative PCR kit (ABI, SYBR TM Select Master Mix, Catalog number: 4472908) to detect the expression level of target gene mRNA in liver tissue. In this real-time fluorescence quantitative PCR method, primers for the target gene and primers for the internal reference gene are used to detect the target gene and the internal reference gene respectively. According to the method described in the instruction manual of the real-time fluorescence quantitative PCR kit, 20μL Real-time PCR reaction system is configured for each PCR detection well. Each reaction system contains 5μL of the cDNA solution obtained by the above reverse transcription reaction, 10μL SYBR TM Select Master Mix, 0.5 μL 10 μM upstream primer, 0.5 μL 10 μM downstream primer, 4 μL RNase-Free H2O. Place the prepared reaction system in a real-time fluorescence quantitative PCR instrument (ABI, StepOnePlus TM), a three-step method was used for Real-time PCR amplification, and the amplification program was 95°C pre-denaturation for 10 minutes, followed by 95°C denaturation for 30 seconds, 60°C annealing for 30 seconds, and 72°C extension for 30 seconds, and the denaturation, annealing, and extension process were repeated for 40 cycles. In this real-time fluorescence quantitative PCR method, the ΔΔCt method was used to perform relative quantitative calculations on the expression level and inhibition rate of the target gene mRNA in each test group, and the calculation method was as follows:

[0413] ΔCt(test group) = Ct(test group target gene) – Ct(test group reference gene)

[0414] ΔCt(control group) = Ct(control group target gene) – Ct(control group internal reference gene)

[0415] ΔΔCt(test group) = ΔCt(test group) – ΔCt(average of control group)

[0416] ΔΔCt(control group) = ΔCt(control group) – ΔCt(control group average)

[0417] Among them, ΔCt (control group average) is the arithmetic mean of the ΔCt (control group) of 5 mice sacrificed at the same time point in the control group. Therefore, each mouse in the test group and the control group corresponds to a ΔΔCt value.

[0418] The target gene mRNA expression level of the test group was normalized with the control group as the benchmark, and the target gene mRNA expression level of the control group was defined as 100%.

[0419] Relative expression level of target gene mRNA in the test group = 2-ΔΔCt (test group) × 100%

[0420] Test group target gene mRNA expression inhibition rate = (1-test group target gene mRNA relative expression level) × 100%

[0421] Unless otherwise stated, the data of in vivo activity experiments are expressed as X±SD, and the experimental data were plotted and analyzed using GraphPadprism 8.0 software.

[0422] Example 1: In vivo activity evaluation of three clusters of CR01022 vectors conjugated with CC3 target siRNA

[0423] In this example, the target gene inhibition activity evaluation method in vivo in mice was used to evaluate the inhibitory activity of the siRNA conjugate RZ802010, which was conjugated with three clusters of CR01022 at the 3' end of the sense strand of the same CC3 target siRNA, and the L96 conjugate RZ502031 on the target gene CC3 in mice.

[0424] 6-8 week old C57BL / 6j mice were randomly divided into groups according to body weight, 15 mice in each group, a total of 3 groups. Each group of mice was given PBS solution and the siRNA conjugate mentioned in the present embodiment by subcutaneous administration in the abdomen, wherein the dosage of each mouse in the PBS control group was 5 ml / kg, and the dosage of each mouse in the siRNA conjugate experimental group was 3 mg / kg (in terms of siRNA), and the administration volume was 5 ml / kg. The day of administration was recorded as the first day (D1), and after administration, 5 mice were killed in each group on the 8th day (D8), 5 mice were killed in each group on the 15th day (D15), and 5 mice were killed in each group on the 29th day (D29). Liver tissue was collected for RNA extraction, reverse transcription reaction and Real-time PCR detection, and the target gene mRNA in each test group was relatively quantitatively calculated according to the aforementioned ΔΔCt method.

[0425] The primer sequences of this example are shown in Table 5.

[0426] Table 5 Primer sequence table of this embodiment

[0427]

[0428] The results of Example 1 show that the conjugate RZ802010, in which the 3' end of the siRNA sense strand is conjugated with three clusters of CR01022, has comparable highest inhibitory activity and better sustained efficacy than the L96 conjugate RZ502031 ( Figure 1 , Table 6).

[0429] Table 6 Inhibitory activity of target genes in mice after administration of the siRNA conjugates described in this example

[0430]

[0431] Example 2: In vivo activity evaluation of two clusters of CR01022 vectors and three clusters of CR01022 vectors conjugated with SOD1 target siRNA

[0432] In this example, the target gene inhibitory activity evaluation method in vivo in mice was used to evaluate the inhibitory activity of the siRNA sequence RZ899009 conjugated with three clusters of CR01022 at the 3' end of the positive strand of the same SOD1 target siRNA, the siRNA sequence RZ899011 conjugated with two clusters of CR01022, and the L96 conjugate RZ599001 on the target gene SOD1 in mice.

[0433] 6-8 week old C57BL / 6j mice were randomly divided into groups according to body weight, 20 mice in each group, a total of 4 groups. Each group of mice was given PBS solution and the siRNA conjugate mentioned in the present embodiment by subcutaneous administration in the abdomen, wherein the dosage of each mouse in the PBS control group was 5 ml / kg, and the dosage of each mouse in the siRNA conjugate experimental group was 1 mg / kg (in terms of siRNA), and the administration volume was 5 ml / kg. The day of administration was recorded as the first day (D1), and after administration, 5 mice were killed in each group on the 8th day (D8), 5 mice were killed in each group on the 15th day (D15), 5 mice were killed in each group on the 29th day (D29), and 5 mice were killed in each group on the 43rd day (D43). Liver tissue was collected for RNA extraction, reverse transcription reaction and Real-time PCR detection, and the target gene mRNA in each test group was relatively quantitatively calculated according to the aforementioned ΔΔCt method.

[0434] The primer sequences of this example are shown in Table 7.

[0435] Table 7 Primer sequence list

[0436]

[0437] The results of Example 2 show that the siRNA sequence RZ899009 conjugated with three clusters of CR01022 at the 3' end of the siRNA sense strand and the siRNA sequence RZ899011 conjugated with two clusters of CR01022 have basically the same highest inhibitory activity and sustained efficacy on the target gene SOD1, and are both superior to the L96 conjugated sequence RZ599001 ( Figure 2 , Table 8).

[0438] Table 8 Inhibitory activity of target genes in mice after administration of the siRNA conjugates described in this example

[0439]

[0440] Example 3: In vivo activity evaluation of one cluster of CR01022 vectors and two clusters of CR01022 vectors conjugated with SOD1 target siRNA

[0441] In this example, the in vivo target gene inhibitory activity evaluation method of mice was used to evaluate the inhibitory activity of the same SOD1 target siRNA in vivo, including the siRNA sequence RZ899011 conjugated with two clusters of CR01022 vectors at the 3' end of the positive strand, the siRNA sequence RZ899040 conjugated with one cluster of CR01022, and the L96 conjugate RZ599001, on the target gene SOD1.

[0442] 6-8 week old C57BL / 6j mice were randomly divided into 4 groups according to body weight, 5 mice in each group. Each group of mice was given PBS solution and the siRNA conjugate mentioned in this embodiment by subcutaneous administration in the abdomen, wherein the dosage of each mouse in the PBS control group was 5 ml / kg, and the dosage of each mouse in the siRNA conjugate experimental group was 1 mg / kg (in terms of siRNA), and the administration volume was 5 ml / kg. The day of administration was recorded as the first day (D1), and mice were killed on the 8th day (D8) after administration. Liver tissue was collected for RNA extraction, reverse transcription reaction and Real-time PCR detection, and the target gene mRNA in each test group was relatively quantitatively calculated according to the aforementioned ΔΔCt method.

[0443] The primer sequences of this example are shown in Table 7 in Example 2.

[0444] The results of Example 3 show that the siRNA sequence RZ899011 conjugated with two clusters of CR01022 and the siRNA sequence RZ899040 conjugated with one cluster of CR01022 at the 3' end of the siRNA sense strand can produce a highly effective inhibitory effect on the target gene SOD1 at D8, and the inhibitory activity is basically equivalent, and both are slightly better than the L96 conjugate RZ599001 ( Figure 3 , Table 9).

[0445] Table 9 Inhibitory activity of target genes in mice after administration of the siRNA conjugates described in this example

[0446]

[0447] Example 4: In vivo activity evaluation of three clusters of CR01023 vectors conjugated with CC3 target siRNA

[0448] This example uses a method for evaluating the in vivo target gene inhibition activity in mice to evaluate the inhibitory activity of the siRNA sequence RZ802011 conjugated to three clusters of CR01023 vectors at the 3' end of the sense strand of siRNA, and the L96 conjugate RZ502031 on the target gene CC3 in mice.

[0449] 6-8 week old C57BL / 6j mice were randomly divided into groups according to body weight, 15 mice in each group, a total of 3 groups. Each group of mice was given PBS solution and the siRNA conjugate mentioned in this embodiment by subcutaneous administration in the abdomen, wherein each mouse in the PBS control group was given a dose of 5 ml / kg, and each mouse in the siRNA conjugate experimental group was given a dose of 3 mg / kg (in terms of siRNA), and the administration volume was 5 ml / kg. The day of administration was recorded as the first day (D1), and after administration, 5 mice were killed in each group on D8, 5 mice were killed in each group on D15, and 5 mice were killed in each group on D29. Liver tissue was collected for RNA extraction, reverse transcription reaction and Real-timePCR detection, and the target gene mRNA in each test group was relatively quantitatively calculated according to the aforementioned ΔΔCt method.

[0450] The primer sequences of this example are shown in Table 5 in Example 1.

[0451] The results of Example 4 show that the three-cluster CR01023 conjugate RZ802011 and the L96 conjugate RZ502031 have comparable overall activity at D8 and D15, but the L96 conjugate RZ502031 has a relatively higher target gene inhibition effect at D29. Figure 4 , Table 10).

[0452] Table 10 Inhibitory activity of target genes in mice after administration of the siRNA conjugates described in this example

[0453]

[0454] Example 5: In vivo activity evaluation of two clusters of CR01027 vectors and two clusters of CR01022 vectors conjugated with SOD1 target siRNA

[0455] This example uses the method for evaluating the in vivo target gene inhibition activity in mice to evaluate the inhibitory activity of the siRNA sense strand 3' end conjugated with the siRNA sequence RZ899048 of the two clusters of CR01027 vectors, the siRNA sequence RZ899011 of the two clusters of CR01022 vectors, and the conjugate RZ599001 conjugated with L96 on the target gene SOD1 in mice. The difference is that CR01027 adds a methoxy group at the 1 position of the CR01022 mother core structure.

[0456] 6-8 week old C57BL / 6j mice were randomly divided into 4 groups according to body weight, 5 mice in each group. Each group of mice was given the siRNA conjugate mentioned in this embodiment by subcutaneous administration in the abdomen, wherein each mouse in the PBS control group was given a dose of 5 ml / kg, and each mouse in the siRNA conjugate experimental group was given a dose of 3 mg / kg, and the administration volume was 5 mL / kg. The day of administration was recorded as the first day (D1), and 5 mice were killed in each group on the 8th day (D8) after administration. Liver tissue was collected for RNA extraction, reverse transcription reaction and Real-time PCR detection, and the target gene mRNA in each test group was relatively quantitatively calculated according to the aforementioned ΔΔCt method.

[0457] The primer sequences of this example are shown in Table 7 in Example 2.

[0458] The results of Example 5 show that the conjugate RZ899048 of the second cluster CR01027 has a higher target gene inhibition effect at D8 than the L96 conjugate RZ599001, and the effect is comparable to the conjugate (RZ899011) of the second cluster CR01022 ( Figure 5 , Table 11).

[0459] Table 11 Inhibitory activity of target genes in mice after administration of the siRNA conjugates described in this example

[0460]

[0461] Example 6: In vivo activity evaluation of two clusters of CR01017 vectors and two clusters of CR01022 vectors conjugated with SOD1 target siRNA

[0462] This example uses a method for evaluating the inhibitory activity of target genes in vivo in mice to evaluate the inhibitory activity of the 3' end of the positive strand of the SOD1 target siRNA conjugated with two clusters of CR01017 vectors, siRNA sequence RZ899038, two clusters of CR01022 vectors, and L96 conjugate RZ599001 on the target gene SOD1 in mice. The main difference between the two clusters of CR01017 vectors and the two clusters of CR01022 vectors is that the linker part of the CR01017 vector is an amide bond structure, and the linker part of the CR01022 vector is a triazole structure.

[0463] 6-8 week old C57BL / 6j mice were randomly divided into groups according to body weight, 15 mice in each group, a total of 4 groups. Each group of mice was given PBS solution and the siRNA conjugate mentioned in the present embodiment by subcutaneous administration in the abdomen, wherein each mouse in the PBS control group was given a dose of 5 ml / kg in the administration volume, and each mouse in the siRNA conjugate experimental group was given a dose of 3 mg / kg (in terms of siRNA), and the administration volume was 5 ml / kg. The day of administration was recorded as the first day (D1), and after administration, 5 mice were killed in each group on the 8th day (D8), 5 mice were killed in each group on the 29th day (D29), and 5 mice were killed in each group on the 54th day (D54). Liver tissue was collected for RNA extraction, reverse transcription reaction and Real-time PCR detection, and the target gene mRNA in each test group was relatively quantitatively calculated according to the aforementioned ΔΔCt method.

[0464] The primer sequences of this example are shown in Table 7 in Example 2.

[0465] The results of Example 6 show that the in vivo activity of the siRNA sense strand 3' end conjugated with the siRNA sequence RZ899038 of the two clusters CR01017 vector and the siRNA sequence RZ899011 of the two clusters CR01022 vector is better than that of the L96 conjugated sequence RZ599001, and the use of the linker triazole structure (CR01022) or amide structure (CR01017) has little effect on the vector activity ( Figure 6 , Table 12).

[0466] Table 12 Inhibitory activity of target genes in mice after administration of the siRNA conjugates described in this example

[0467]

[0468] Example 7: In vivo activity evaluation of different amounts and locations of CR01017 conjugated to SOD1 target siRNA

[0469] In this example, the target gene inhibitory activity evaluation method in vivo in mice was used to evaluate the inhibitory activity of siRNA sequence RZ897041 with a cluster of CR01017 vectors conjugated to the 3' end of the siRNA sense chain, siRNA sequence RZ897042 with a cluster of CR01017 vectors conjugated to the 5' and 3' ends of the siRNA sense chain, siRNA sequence RZ897038 with two clusters of CR01017 vectors conjugated to the 3' end of the siRNA sense chain, and L96 conjugate RZ599001 on the target gene SOD1 in mice.

[0470] 6-8 week old C57BL / 6j mice were randomly divided into groups according to body weight, 15 mice in each group, a total of 5 groups. Each group of mice was given PBS solution or siRNA conjugates mentioned in this embodiment by subcutaneous administration in the abdomen, wherein each mouse in the PBS control group was given a dose of 5 ml / kg in the administration volume, and each mouse in the siRNA conjugate experimental group was given a dose of 3 mg / kg (in terms of siRNA), and the administration volume was 5 ml / kg. The day of administration was recorded as the first day (D1), and after administration, 5 mice were killed in each group on the 8th day (D8), 5 mice were killed in each group on the 29th day (D29), and 5 mice were killed in each group on the 54th day (D54).

[0471] The primer sequences of this example are shown in Table 7 in Example 2.

[0472] The results of Example 7 show that the siRNA conjugate RZ899038, in which the 3' end of the siRNA sense strand is conjugated to a two-cluster CR01017 vector, the siRNA conjugate RZ899041, in which the 3' end of the siRNA sense strand is conjugated to a one-cluster CR01017 vector, and the siRNA conjugate RZ899042, in which the 5' end and the 3' end of the siRNA sense strand are conjugated to a one-cluster CR01017 vector, respectively, have an inhibitory effect comparable to that of the L96 conjugate RZ599001 at D8 and D29, and have a higher inhibitory effect on the target gene than the L96 conjugate RZ599001 at D59. This indicates that the CR01017 conjugate has a longer duration of pharmacodynamic action ( Figure 7 , Table 13).

[0473] Table 13 Inhibitory activity of target genes in mice after administration of the siRNA conjugates described in this example

[0474]

[0475] Example 8: The present disclosure selects two clusters of CR01022 conjugated with SOD1 target siRNA sequence RZ899011 and two clusters of CR01017 vector conjugated with SOD1 target siRNA sequence RZ899038 for in vivo toxicity evaluation in mice

[0476] In this example, subcutaneous injection was used to evaluate the nature and extent of the toxicity of the siRNA sequence RZ899011 conjugated with two clusters of CR01022 and the siRNA sequence RZ899038 conjugated with two clusters of CR01017 vectors in ICR mice.

[0477] ICR mice aged 6-8 weeks were randomly divided into groups according to body weight, with 10 mice (half male and half female) in each group, for a total of 3 groups. Each group of mice was subcutaneously administered with PBS solution (without siRNA conjugate) or the siRNA conjugate mentioned in this example, wherein each mouse in the PBS control group was administered with a dose of 10 ml / kg mouse body weight, and each mouse in the siRNA conjugate administration group was administered with a dose of 300 mg / kg mouse body weight (in terms of siRNA), and the administration volume was 10 ml / kg.

[0478] The day of administration was recorded as the first day (D1), and clinical observation was performed at least once a day after the first administration during the experiment; blood was collected from all animals on the 15th day of the experiment (recorded as D15) (mice were fasted for at least 12 hours before sampling and testing, but water was not allowed) for hematological and blood biochemical tests. The collected blood was anticoagulated with EDTA-K2, and a routine blood test was performed using an automatic modular blood and body fluid analyzer (Sysmex XN-10B1); the collected blood was anticoagulated with sodium citrate, centrifuged at room temperature for 10 minutes (centrifugal force of about 2000g), and the plasma was separated and tested for coagulation indexes using a fully automatic coagulation analyzer (Mindray C3510); blood samples (without anticoagulation) were collected and placed at room temperature for about 30 minutes. After the blood coagulated, it was centrifuged at 2000g for 10 minutes at 4°C, and a fully automatic biochemical analyzer (Sysmex BX-4000) was used for blood biochemical testing. All animals were dissected on the 15th day of the experiment (denoted as D15). The mice to be dissected had to fast but not deprive of water for at least 12 h before dissection, and were anesthetized with Zotal 50 (Vicki Co., Ltd., France, 8G4VA). After blood collection, the animals were euthanized by bleeding from the abdominal aorta, and their gross anatomical observations were performed. The livers of all animals were subjected to histopathological examination (using hematoxylin-eosin staining), and if necessary, histopathological examinations were performed on organs with obvious abnormal changes in size, shape, color, texture, etc.

[0479] The primer sequences of this example are shown in Table 7 in Example 2.

[0480] The results of Example 8 show that after the siRNA conjugates shown in this example, no abnormalities were found in the clinical observations of the PBS group, the RZ899011 group, and the RZ899038 group during the experiment; at the end point of the experiment, D15, no obvious abnormalities were found in the gross anatomy; no abnormalities were found in the hematology and blood biochemistry tests of the animals in each group ( Figure 8a -j, Table 14); no abnormalities were found in the histopathological staining of the liver tissues of the animals in each group ( Figure 8k ); indicating that the siRNA conjugates and their carrier molecules disclosed in the present invention have good safety and low animal level toxicity.

[0481] Table 14 Hematological and blood biochemical test results of mice after administration of the siRNA conjugates described in this example

[0482]

[0483] It is to be understood that the above embodiments are merely exemplary embodiments used to illustrate the principles of the present disclosure, but the present disclosure is not limited thereto. For those of ordinary skill in the art, various modifications and improvements can be made without departing from the spirit and substance of the present disclosure, and these modifications and improvements are also considered to be within the scope of protection of the present disclosure.

Claims

1. A compound represented by formula (I) or a stereoisomer thereof: In formula (I), p and q are each independently selected from 0, 1, 2 or 3; Each n is independently selected from 1, 2, 3, 4 or 5; R 1 Select from H or R 1 ', the R 1 ' is selected from hydroxyl protecting groups; R 2 Select from H or R 2 ', the R 2 'Selected from in, R 2a Selected from secondary amino groups, R 2b is selected from C substituted with secondary amino or cyano 1 -C 3 Alkoxy; R 3 Select from H or C 1 -C 3 Alkoxy; Each R 4 Each independently selected from 2. The compound according to claim 1, It is characterized in that Each R 4 All selected from 3. The compound according to claim 1, It is characterized in that Each R 4 All selected from 4. The compound according to claim 1, It is characterized in that p and q are each independently selected from 0 or 1; Optionally, p=1 and q=1, or p=1 and q=0, or p=0 and q=1, or p=0 and q=0; Optionally, p=1 and q=0; Optionally, each n is selected from 1, or each n is selected from 2, or each n is selected from 3, or each n is selected from 4, or each n is selected from 5; Optionally, each n is selected from 1; Optionally, the structural formula of the hydroxyl protecting group is Among them, each R 1a Each independently selected from H, C 1 -C 3 Alkyl or C 1 -C 3 Alkoxy; Optionally, each R 1a Each independently selected from H or methoxy; Optionally, the hydroxy protecting group is selected from a trityl group (Tr group), a 4-methoxytrityl group (MMTr group), a 4,4'-dimethoxytrityl group (DMTr group) or a 4,4',4"-trimethoxytrityl group (TMTr group); Optionally, the hydroxy protecting group is selected from 4,4'-dimethoxytrityl (DMTr group). Optionally, R 2a Selected from Optionally, R 2b Selected from Optionally, R 2b Selected from Optionally, Selected from Optionally, Selected from 5. The compound according to claim 1, It is characterized in that The compound is selected from any of the following structures:

6. The compound according to claim 1, It is characterized in that The compound is selected from any of the following structures:

7. A method for preparing a compound, It is characterized in that The compound is as shown in formula (I-1a) or formula (I-1b) or formula (I-1c): Among them, R 1 '、R 2 '、R 3 , p, q, n are as defined in any one of claims 1 to 6; The preparation method comprises the following steps: S1-1, the compound of formula (1) and the compound of formula (2) undergo acetalization reaction in the presence of an acidic catalyst to obtain a compound of formula (3); wherein R 5 Selected from phenyl (Ph group); S1-2, the compound of formula (3), the hydrogenated salt and the compound of formula (4) undergo electrophilic substitution reaction to obtain a compound of formula (5); wherein X 1 represents halogen; S1-3, the compound of formula (5) undergoes a dehydroxylation reaction under acidic conditions to obtain a compound of formula (I-1a); S1-4, the compound of formula (I-1a) and the compound of formula (6) undergo nucleophilic substitution reaction to obtain a compound of formula (I-1b); wherein X 2 represents halogen; S1-5, the compound of formula (I-1b) and the compound of formula (7) undergo condensation reaction to obtain a compound of formula (I-1c); wherein R 2c is selected from halogen or secondary amino; Optionally, in step S1-1, the molar ratio of the compound of formula (1), the compound of formula (2) and the acidic catalyst is 1:(2-4):(0.01-0.2); for example, 1:3:0.1; Optionally, in step S1-1, the acidic catalyst is selected from DL-10-camphorsulfonic acid; Optionally, in step S1-1, the reaction temperature of the acetalization reaction is selected from 20 to 40° C.; Optionally, in step S1-2, the molar ratio of the compound of formula (3), the compound of formula (4) and the catalyst is 1:(3-5):(3-5), for example 1:4:4; Optionally, in step S1-2, the hydride salt is selected from sodium hydride, potassium hydride or magnesium hydride; Optionally, in step S1-2, the conditions of the electrophilic substitution reaction are: the compound of formula (3) and the hydrogenated salt are first reacted at -10 to 0°C for 25 to 35 minutes, and then the compound of formula (4) is added and reacted at 20 to 40°C for 1 to 5 hours; Optionally, in step S1-3, the acidic condition is: an organic acid; Optionally, in step S1-3, the acidic condition is: acetic acid; Optionally, in step S1-3, the reaction temperature of the dehydroxylation protection reaction is selected from 60 to 80° C.; Optionally, in step S1-4, the molar ratio of the compound of formula (I-1a) to the compound of formula (6) is 1:(1.1-1.5); Optionally, in step S1-4, the compound of formula (6) is selected from trityl chloride, trityl bromide, 4-methyltrityl chloride, 4-methoxytrityl chloride, 4,4'-dimethoxytrityl chloride or 4,4',4"-trimethoxytrityl chloride; Optionally, in step S1-4, the compound of formula (6) is selected from 4,4'-dimethoxytrityl chloride; Optionally, in step S1-4, the nucleophilic substitution reaction is carried out in an inert atmosphere; Optionally, in step S1-4, the reaction temperature of the nucleophilic substitution reaction is selected from 20 to 40° C.; Optionally, in step S1-5, the molar ratio of the compound of formula (I-1b) to the compound of formula (7) is 1:(0.6 to 0.9); Optionally, in step S1-5, the compound of formula (7) is selected from 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite, bis(diisopropylamino)chlorophosphine and bis(diisopropylamino)(2-cyanoethoxy)phosphine. Optionally, in step S1-5, the condensation reaction is carried out in an inert atmosphere.

8. A method for preparing a compound, It is characterized in that The compound is shown in formula (I-2): Among them, R 1 '、R 3 , p, q, n are as defined in any one of claims 1 to 6; The preparation method comprises the following steps: S2-1, the compound of formula (3), the hydride salt, the compound of formula (8) and the iodide salt undergo electrophilic substitution reaction to obtain a compound of formula (9); wherein R 5 is selected from substituted or unsubstituted C6-C12 aryl groups, X 3 Represents halogen, R 6 Selected from substituted or unsubstituted C1-C5 alkyl; S2-2, the compound of formula (9) undergoes a dehydroxylation reaction under acidic conditions to obtain a compound of formula (10); S2-3, the compound of formula (10) and the compound of formula (6) undergo a nucleophilic substitution reaction to obtain a compound of formula (11); S2-4, the compound represented by formula (11) undergoes hydrolysis reaction to obtain a compound represented by formula (I-2); Optionally, in step S2-1, the molar ratio of the compound of formula (3), the hydride salt, the compound of formula (8) and the iodide salt is 1:(3-5):(1.5-2.5):(1-2); for example, 1:4:2:1.5; S2-1, the conditions of the electrophilic substitution reaction are: the compound of formula (3) and the hydrogenated salt are first reacted at -10 to 0°C for 0.5 to 1.5 hours, and then the compound of formula (8) and the iodide salt are added and reacted at 20 to 40°C for 3 to 5 hours; Optionally, in step S2-1, R 5 Selected from phenyl (Ph group); Optionally, in step S2-1, R 6 is selected from substituted or unsubstituted C1-C3 alkyl; Optionally, in step S2-1, R 6 Selected from ethyl; Optionally, in step S2-2, the acidic condition is: an organic acid; Optionally, in step S2-2, the acidic condition is: acetic acid; Optionally, in step S2-2, the reaction temperature of the dehydroxylation protection reaction is selected from 40 to 60° C.; Optionally, in step S2-3, the molar ratio of the compound of formula (10) to the compound of formula (6) is 1:(1.1-1.5), for example 1:1.3; Optionally, in step S2-3, the reaction temperature of the nucleophilic substitution reaction is selected from 20 to 40°C; Optionally, in step S2-4, the hydrolysis reaction is selected from an alkaline hydrolysis reaction; Optionally, in step S2-4, the hydrolysis reaction conditions are selected from 0.5 to 1.5 mol / L NaOH aqueous solution, such as 1 mol / L NaOH aqueous solution; Optionally, in step S2-4, the temperature of the hydrolysis reaction is 20-40°C.

9. Use of the compound according to any one of claims 1 to 6 in the preparation of a targeting ligand capable of binding to a cell surface receptor; Optionally, the receptor is selected from asialoglycoprotein receptors.

10. Use of a compound according to any one of claims 1 to 6 in the preparation of a drug for reducing the expression or activity of a specific gene in a target cell; Optionally, the target cells are selected from hepatocytes; Optionally, the drug is selected from RNAi drugs; Optionally, the drug is selected from siRNA drugs.

Citation Information

Patent Citations

  • Branched chain-type derivative having glucoskeleton

    JP1994009675A

  • N-ACETYLGALACTOSAMINE(GAlNAc)-DERIVED COMPOUNDS AND OLIGONUCLEOTIDES

    WO2022076922A1

  • Nucleic acid ligand and conjugate thereof, and preparation method therefor and use thereof

    WO2023274395A1

Cited By

  • Polypeptide ligand for mediating targeted natriuretic peptide receptor and application thereof

    CN121362229A

  • Oligonucleotide conjugates containing kidney delivery vectors

    CN122140750A

  • Oligonucleotide conjugates for the treatment of polycystic kidney disease and uses thereof

    CN122954970A

  • Extrahepatic delivery ligand and conjugate thereof

    WO2025261376A1